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Abstract  
 
Skeletal muscle constitutes ~40% of the body mass in metazoans and plays a crucial role 
throughout life. Skeletal muscle development prenatally and regeneration postnatally are critical 
for animal life. Unlike cardiac and smooth muscle, skeletal muscle maintains a robust regenerative 
capacity postnatally due to resident muscle stem cells, also known as satellite cells. Similar to 
skeletal muscle development, skeletal muscle regeneration is also a well orchestrated process. 
Many transcriptions factors and signaling pathways have been documented to be involved in this 
process, such as the myogenic regulatory factors (MRFs), the activator protein 1 (AP-1) family 
transcription factors and Notch signaling. Compared to MRFs, AP-1 is not a muscle-specific 
transcription factor, and its role in skeletal muscle regeneration and the mechanisms involved are 
still not well characterized. Similarly, the roles of signaling pathways during regeneration are much 
less defined in comparison to their role during development. Therefore, the purpose of this body 
of work was to investigate the role of AP-1 in myogenic progenitor cells. 
Components of AP-1 have dynamic expression profiles during myogenesis in C2C12 cells, the 
expression profile of AP-1 is different among proliferative myoblasts, differentiating myoblasts, 
differentiated myotubes and reserve cells, indicating context-dependent spatial and temporal roles. 
We found that the expression profile of Fra-2/AP-1 is also dynamic in cultured single fibers, which 
harbor satellite cells. We observed Pax7 mRNA level went down accompanied with precocious 
differentiation upon konckdown of Fra-2, suggesting that Fra-2 may play a role in determining the 
fate of satellite cells by modifying the expression of the key specification factor, Pax7. In addition, 
inhibition of ERK 1/2 MAPK pathway, a known upstream kinase of Fra-2, led to the loss of Fra-
2 and Pax7 expression at protein level.  
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Furthermore, loss of function using siRNA technology indicated that the effect of AP-1 on 
Notch signaling and its downstream target genes in satellite cells is Fra-2 specific, while c-Jun did 
not have the same effect. Fra-2 was also found to modulate the expression of Sbno1, a novel 
downstream effector of Notch signaling in myogenic cells. 
In conclusion, this work provides some insight into the role of Fra-2/AP-1 in the regulation of 
satellite cells by looking into how Fra-2 might determine the fate of satellite cells by modulating 
the expression of Pax7.  
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Review of literature 
 
AP-1: Activator Protein-1 Transcription Factor 
 
AP-1 is a ubiquitously expressed transcription factor, its expression and activity are induced by 
an array of physiological and environmental stimuli. In turn, AP-1 regulates a wide range of 
cellular processes, including cell proliferation, cell death and survival, differentiation and 
regeneration [1–5]. However, despite increasing insight into the physiological functions of AP-1, 
signalling pathways involved in regulating these functions and the target-genes mediating these 
functions are not well understood. As one of the first mammalian transcription factors identified 
[6], the complex physiological functions of AP-1 are still being unravelled. 
 
1. 1 AP-1 components and structure 
 
Activator protein 1 (AP-1) is a dimeric transcription factor consisting of basic region-leucine 
zipper (bZIP) proteins that belong to Jun and Fos, the closely related activating transcription 
factors (ATF) and the Maf subfamily [6–10].  
Jun family proteins include c-Jun, JunB and JunD, which may form homodimers or 
heterodimers with members of the Fos family members. Members of the Fos family are c-Fos, 
FosB, Fra-1 and Fra-2, which can only form heterodimeric complexes with Jun members [11–13]. 
ATF proteins include CREB, ATF1, ATF2, LRF1/ATF3, B-ATF, which may form homodimers 
as well as heterodimers with Jun proteins [14]. There are two additional Jun dimerization partners 
(JDP), JDP1 and JDP2 [7]. Maf subfamily, which includes c-Maf, MafB, MafA, MafG/F/K and 
Nrl, is the least studied in terms of its activity [4,10].  
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AP-1 transcription factors harbour a basic DNA-binding domain and leucine zipper domain. 
The basic domain is responsible for DNA binding in a sequence specific manner. The leucine 
zipper domain mediates dimerization with other bZIP proteins. The transactivation domain 
regulates the transactivation activity (Figure 1). Dimerization between AP-1 components is a pre-
requisite for DNA binding, occuring via hydrophobic interactions of leucine residues in the leucine 
zipper domain [6]. Although Jun proteins may form homodimers, Fos proteins do not form 
homodimers but can bind to DNA by forming Fos:Jun heterodimers that are more stable than 
Jun:Jun homodimers [11,15]. In mammalian cells, Jun:Jun and Fos:Jun dimers bind to a specific 
DNA sequence known as the phorbol 12-O-tetradecanoate-13- acetate (TPA) response element 
(TRE) (5'-TGAG/CTCA-3'), which can mediate transcriptional induction and tumor induction by 
TPA treatment [16]. In yeast, a Jun homologue, Gcn4p, recognizes the same DNA element 
indicating extensive evolutionary conservation of this cis element [2,17]. AP-1 complexes 
containing ATF, on the other hand, preferentially bind to the cAMP responsive elements (CRE, 
5'-TGACGTCA- 3') [18]. JDP1 and JDP2 bind to both TRE and CRE [7]. 
Jun and Fos proteins differ significantly in terms of their DNA binding affinities and 
transactivation properties. c-Jun, c-Fos and FosB exhibit strong transactivation potential, while 
JunB, JunD, Fra-1 and Fra-2 are considered as weak transactivators. Each of these proteins is 
expressed and regulated differently. Different AP-1 dimer compositions exhibit differential 
promoter binding specificity and transactivation potential [8,14,19,20]. Hetero-dimerization with 
c-Fos enhances the transcriptional potential of c-Jun by forming a more stable dimer [11,15]. 
Hetero-dimerization with FosB, however, antagonizes c-Jun transcriptional potential [19,21]. 
Jun:ATF2 and Jun:Fos dimers promote tumor growth in  melanoma, ATF2:ATF2 dimer, on the 
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other hand, inhibits that function  [22,23]. Thus the relative expression of AP-1 subunits and their 
composition play critical roles in determining cell fate [20,21]. 
 
 
Figure 1: Schematic diagram showing the function domains (A) and dimerization and DNA binding properties 
(B) of AP-1. A: the locations of functional domains are indicated. N, amino terminus; TAD, transcription-activating 
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domain; DBD, DNA binding domain; LZD, leucine-zipper domain; C, carboxyl terminus. B: LZD mediates the 
dimerization between AP-1 components and is required for DNA binding. ATF, activation transcription factor; TRE, 
12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element; CRE, cyclic AMP-responsive element. Note that 
CRE has an extra base (underlined) compared with TRE. 
 
1.2 AP-1 function 
 
AP-1 regulates both basal and inducible transcription of numerous genes containing AP-1 
binding sites in their cis-regulatory regions. Each Jun protein exhibits unique roles, but Fos 
proteins show some functional redundancy [6]. AP-1 proteins are expressed in virtually all 
vertebrate cell types and some viruses, indicating that its activity is quite ubiquitous (Figure 2). 
AP-1 components are also found expressed and regulated differentially, which means that there 
are also elements of specificity wired into AP-1 complex function  [24]. 
  
Figure 2: Schematic view of AP-1 functions. Activation of MAPK pathways by extracellular stimuli induces the 
post-translational modification of AP-1 subunits. Subsequently AP-1 translocates into the nucleus and drives target 
gene expression. AP-1 regulates a wide range of cellular processes as indicated above. The exact outcome is 
determined by the nature of the extracellular stimulus.  
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Loss-of-function experiments using ES cell technology and use of animal models has provided 
further understanding regarding the specific functions of different AP-1 components in mouse 
development. Absence of c-Jun results in embryonic lethality in mice due to defects in the heart, 
artery and liver [25–27]. Conversely, broad overexpression of c-Jun in transgenic mice does not 
affect morphological phenotype [28]. c-Jun regulates eyelid closure and skin tumor development 
through regulation of EGFR and HB-EGF [29]. Lack of JunB causes embryonic lethality between 
E8.5 and E10.0 due to vascular defects in the extra-embryonic tissues [30]. JunB is an important 
regulator in erythroid differentiation and a positive regulator in primarily controlling osteoblast as 
well as osteoclast activity [31,32]. JunB is also essential for endothelial cell morphogenesis by 
regulating core-binding factor β [33]. JunD deficient mice are viable. However, mutant males 
exhibit reduced postnatal growth, abnormalities in head hormone balance and defects in 
reproduction due to compromised spermatogenesis, while no defects in fertility were observed in 
female counterparts [34]. JunB and JunD can both regulate the differentiation and function of T 
helper (Th) cells by regulating cell-specific cytokines. JunB promotes Th2 lineage differentiation 
through regulating cyclinA, whereas JunD inhibits it by negatively affecting IL-4 expression 
[35,36].  Mice lacking c-Fos are viable and fertile but with an osteopetrotic phenotype due to lack 
of osteoclasts [37,38]. Prolonged expression of c-Fos is shown to stimulate osteoclast 
differentiation [39]. c-Fos expression is also induced during myelomonocytic differentiation and 
macrophage proliferation [40],  while constitutive and inducible overexpression of c-Fos is 
reported to inhibit chondrocyte differentiation in vitro [41]. Mice lacking FosB develop normally 
although some adult mutant females display impaired nurturing behaviour [42,43]. Overexpression 
of DFosB, a dominant negative form of FosB [44–46], promotes differentiation in osteoblasts, 
while ectopic expression of DFosB in thymocytes disrupts normal T cell differentiation [47,48]. 
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Induced FosB expression initiates osteogenic differentiation of mesenchymal cells through the 
upregulation of osteoblast genes [49]. Inactivation of Fra-1 leads to embryonic lethality due to 
abnormalities in the placenta and the yolk sac. Fra-1 deficient mice can be partly rescued and 
develop without obvious abnormalities. Ectopic Fra-1 expression is able to rescue Fra-1 knockout 
phenotype and promote osteoblast [50], indicating Fra-1 is dispensable for differentiation. 
However, embryo-specific Fra-1 knockout mice display osteopenia [32]. Fra-1 is also shown to 
inhibit follicular B cell differentiation into plasma cells by repressing Blimp1 expression [51]. 
Pups lacking Fra-2 die shortly after birth and exhibit defects in chondrocytes and osteoclasts 
[52,53]. Ectopic Fra-2 expression in transgenic mice perturbs normal eye development by 
contributing to TGF alpha signalling events [54]. Induced expression of Fra-2 is reported to cause 
pulmonary fibrosis in mice, possibly by bridging vascular remodeling and fibrogenesis [55]. 
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-
2/AP-1. Fra-2 regulates B cell development by acting as an upstream regulator of IRF4 at multiple 
stages [56]. 
Table 1 Analysis of Jun and Fos knock-out mice 
gene Phenotype(s) Affected organ(s)/cell type(s) 
c-Jun Embryonic lethality Liver/hepatoblasts, Heart/outflow tract 
JunB Embryonic lethality Extra-embryonic tissue/giant trophoblasts, yolk sac; Placenta/labyrinth layer 
JunD Male sterility Testis/spermatogenesis 
c-Fos Osteopetrosis Bone/osteoclasts 
FosB Nurturing defect Brain/hypothalamus 
Fra-1 Embryonic lethality Extra-embryonic tissue/yolk sac; Placenta/labyrinth layer 
Fra-2 Osteopetrosis Bone/osteoclasts 
 
AP-1 regulates cell proliferation, cell-cycle progression and differentiation mainly through its 
ability to modulate the expression of cell-cycle regulators such as cyclin D1, cyclin A, cyclin E, 
p53, p21Cip1, p16Ink4a and p19ARF [4,57]. Tissue-specific manipulation of c-Jun in mice has 
7 
 
documented that c-Jun is crucial for cell-cycle regulation in fibroblasts as well as in liver cells and 
keratinocytes [29,58,59]. Hepatocyte proliferation and liver regeneration are impaired in liver-
specific deletion of c-Jun expression in mice [58]. Consistent with this finding, an early study 
showed that c-Jun expression was elevated during the expansion of liver cells [27]. c-Jun and JunB 
antagonistically regulate the proliferation and differentiation of fibroblasts during the formation of 
epithelia [60]. In agreement with this, c-Jun is found to promote epidermal neoplasia, whereas 
JunB inhibits it [61]. JunB is reported to inhibit proliferation in B-lymphoid cells, cell proliferation 
is enhanced in the absence of JunD in lymphocytes, indicating that JunB and JunD can also act as 
negative regulators of cell proliferation [36,62]. However, intriguingly JunB can substitute for c-
Jun in mouse development and cell proliferation [63].  Thus, JunB plays a positive role in 
proliferation in the absence of c-Jun, and a negative one in the presence of c-Jun. JunD exhibits a 
similar role switch that depends on the presence of menin [64]. The fact that AP-1 can both 
promote and inhibit cell-cycle progression and proliferation are most likely due to the relative 
expression of distinct members and dimer compositions within the cell. 
AP-1 was first identified as a transcription factor in HeLa cell extracts that binds to the promoter 
and enhancer region of the human metallothionein IIA gene and simian virus SV40 [65].  Since 
the Fos and Jun genes were initially found and studied in the genomes of oncogenic retroviruses, 
the connection of AP-1 to cancer has been immediately established. The first AP-1 component 
reported in mammalian tumors was c-Fos, c-Fos was reported sufficient to induce transformation 
of immortalized rat fibroblasts [66]. c-fos mRNAs were induced in small cell lung cancer cell upon 
bombesin treatment and is required for malignant progression of skin tumors [67,68]. Though c-
Fos is conventionally considered to be oncogenic, c-Fos was recently reported to inhibit ovarian 
cancer progression by changing adhesion properties [69]. Constitutive expression of FosB and its 
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short form, FosB/SF, promotes proliferation and induces malignant cell transformation in rat-1A 
cells [70]. Surprisingly, FosB transgenic mice do not develop tumors [28].  Fra-1 and Fra-2 exhibit 
weak transforming potential comparing with the other Fos members. Fra-1 plays a critical role in 
the development of epithelial tumors through inducing morphological transformation and 
increasing in vitro invasiveness and motility of epithelial cells [71]. Fra-1 is suggested to promote 
breast cancer progression through regulating proliferation and invasiveness of breast cancer cells 
[72]. Though transgenic mice overexpressing Fra-2 do not develop tumors in a broad range of 
organs, Fra-2 overexpression is suggested to promote a more aggressive tumor phenotype and is 
probably involved in breast cancer progression by changing cellular adhesion properties [54,73,74]. 
In vitro studies show that c-Jun, the cellular homologue of v-Jun, causes oncogenic transformation 
in mammalian cells when co-expressed with an activated oncogene such as Ras or Src [19,75]. 
Whereas, c-Jun overexpression in transgenic mice does not promote tumor development [28]. c-
Jun promotes cancer in mice by regulating the classical tumor initiation-tumor promotion process 
[76]. Breast cancer cell tumorigenesis is inhibited when c-Jun degradation is induced [77]. Neither 
JunB nor JunD exhibits transforming potential [78,79]. However, both JunB and JunD are involved 
in tumorigenesis suggesting that they are necessary but not sufficient for tumorigenesis. JunB 
functions as a gatekeeper for B-lymphoid leukemia through regulating the proliferative capacity 
of transformed leukemic cells [80]. In the absence of JunB, tumor angiogenesis is impaired in 
teratocarcinomas due to inability to efficiently recruit host-derived vessels [81]. While loss of 
stromal JunB does not affect tumor growth and angiogenesis [82]. JunD reduces tumor 
angiogenesis by protecting cells from oxidative stress [83]. Recent study also shows that the 
expression levels of JunB, JunD and phosphorylated c-Jun are positively correlated with tumor 
cell proliferation in diffuse large B-cell lymphomas [84]. 
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AP-1 has a dual function in cell survival and apoptosis and the exact outcome is highly context 
dependent.  AP-1 was first linked to apoptosis due to the observation of c-Fos and c-Jun induction 
preceding apoptosis [85–87]. Though such observations do not demonstrate Jun or Fos’s functional 
involvement apoptosis, they opened the gate for more productive studies regarding the role of AP-
1 in apoptosis. Light-induced apoptosis of retinal photoreceptors is impaired in c-Fos-deficient 
mice [88]. Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 
cells [89]. In addition, AP-1 was reported to mediate NO-induced apoptosis in adult 
cardiomyocytes by acting downstream of JNK and ERK signalling pathway [90]. However, AP-1 
is also involved in cell survival, which is anti-apoptotic. c-Jun was shown to protect cells against 
UV-induced cell death and promote cell survival via maintaining mitochondrial integrity and 
expression of the key regulators of ROS production [91–93]. Inhibition of AP-1 transcriptional 
activator function was shown to induce myc-dependent apoptosis in HL60 cells, indicating AP-
1’s anti-apoptotic role [94]. In addition, Fra-2 was recently reported to promote adipocyte survival 
by regulating PPARγ and hypoxia [95]. 
 
1.3 AP-1 regulation 
 
Regulation of AP-1 activity can be achieved through changes of gene transcription and mRNA 
turnover, post-translational modifications and AP-1 subunit turnover, specific dimeric 
compositions of AP-1 subunits, as well as interaction with other transcription factors and cofactors 
[16,96,97] (Figure 3). 
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Figure 3: Schematic representation of MAPK signalling pathways regulating AP-1 proteins. A plethora of 
stimuli including cytokines, stress, and growth factors can activate signalling pathways that will subsequently 
modulate AP-1 and regulate its function.  
 
AP-1 activity is regulated by a complex of physiological and pathological stimuli, including 
growth factors, cytokines, cell-matrix interactions, stress signals and oncogenic stimuli, as well as 
bacterial and viral infections. These stimuli induce the post-translational modification of AP-1 
subunits by mitogen activated protein kinase (MAPK) cascades that lead to enhanced AP-1 
activities [98,99].  
Activation of Jun through the Jun N-terminal kinase (JNK) cascade is one of the most 
extensively documented mechanisms in the case of mitogen/stress-induced post-translational 
control [8,24]. JNKs belongs to the MAPK superfamily and target Jun proteins [100].  JNKs were 
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found to translocate to the nucleus upon activation and phosphorylate c-Jun within its N-terminal 
transactivation domain (residues Ser63 and Ser73), which potentiates the transactivation potential 
of c-Jun [101,102]. JNKs also phosphorylate and enhance the activity of ATF-2 and JunD 
[103,104]. In contrast, JunB phosphorylation by JNK is unclear though it has been proposed that 
Thr102 and Thr104 are target sites [105].  
The extracellular-signal-regulated kinase (ERK) subgroup of MAPKs is another well studied 
pathway that regulates AP-1 activity. When activated by serum and growth factors, ERKs 
translocate to the nucleus, phosphorylate, and subsequently enhance the transcriptional potential 
of ternary complex factors (TCFs) that bind to Fos promoters [106]. Also, the duration of ERK1/2 
activity was shown to determine the activation of c-Fos and Fra-1 and the composition and 
quantitative transcriptional output of AP-1 [107]. Furthermore, ERK1/2 directly phosphorylates 
Fra-1 and Fra-2, stabilizing them and possibly enhancing their DNA binding activity upon serum 
stimulation [5,108]. Though ERKs are mostly involved in the regulation of Fos proteins, ERK5 
was shown to increase c-Jun expression by inducing phosphorylation and activation of the 
transcription factor myocyte specific enhancer binding factor 2C (MEF2C) [109].  
In addition, MEKK1, a MAPK kinase kinase and an ubiquitin ligase that regulates both ERK1/2 
and JNK, was reported to regulate the AP-1 dimer repertoire by controlling JunB transcription and 
Fra-2 protein stability [110] 
Furthermore, p38, another subfamily of MAPKs, phosphorylates c-Fos and enhances AP1-
driven gene expression in response to UV exposure [111]. Though p38 was conventionally linked 
to AP-1 regulation by its ability to directly phosphorylate ATF2, MEF2C and TCFs [112].  
  
12 
 
1.4 AP-1 in skeletal muscle 
 
The role of AP-1 in skeletal muscle has been studied for more than two decades, yet the exact 
functions of this non-muscle-specific transcription factor are still being revealed. The proto-
oncogene c-Jun was first documented to inhibit myogenesis by physically interacting with MyoD 
and suppressing its DNA binding activity [113]. Also c-Fos expression was found greatly 
decreased, which was a direct result of repression of the c-Fos promoter by MyoD upon muscle 
cell differentiation [114]. Interestingly, expression of c-Jun was maintained in mouse C2C12 and 
rat L6 myoblasts undergoing myogenic differentiation, although overexpression of c-Jun has been 
shown to block myogenic differentiation in C2C12 cells, suggesting that expression of c-Jun at 
physiological levels may not interfere with skeletal myogenesis whereas overexpression does 
[115]. This finding was confirmed by a later study, suggesting that the function of AP-1 in 
myogenesis is context and composition dependent [116]. AP-1 composition shifts from a 
predominant c-Fos:c-Jun dimer in myoblasts to a Fra-2:c-Jun/JunD complex in differentiating 
myoblasts [116].  
Apart from its role in myogenesis, AP-1 was also reported to be involved in regulating the size 
of skeletal muscle, which is determined by the balance between overall rates of protein synthesis 
and degradation that are regulated by intracellular signaling networks. Increased AP-1 binding 
activity was observed in skeletal muscle during sepsis, which is associated with increased muscle 
proteolysis [117].  Blocking AP-1 via injection of virus containing the TAM67, a dominant 
negative form of  c-Jun protein, into the gastrocnemius muscle of tumour-bearing rats resulted in 
a significant recovery of the muscle, indicating that AP-1 plays a negative role in protein accretion 
[118]. On the other hand, JunB was shown to maintain skeletal muscle mass and promotes 
hypertrophy through reducing protein breakdown [119]. Those contradictory findings can be partly 
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explained by the fact that in these studies, different AP-1 subunits were being studied and also 
different cellular systems were used. In addition, one study also reported that AP-1 plays a major 
role in skeletal muscle cellular plasticity by regulating the PGC-1α-controlled gene program of the 
hypoxia response [120].  
Most of the studies mentioned above focused on the role of AP-1 in skeletal muscle proliferation 
and differentiation, AP-1 has also been implicated to be important in skeletal muscle regeneration. 
Transcripts for c-Fos and c-Jun genes are expressed in regenerating rat skeletal muscle at 3 h post-
trauma, but the exact functions were not clear [121]. Another study showed that c-Jun 
transcriptional activity was induced upon exercise in human skeletal muscle[122]. In addition, c-
Fos mRNA was induced upon repetitive stretch within several hours in skeletal muscle removed 
from rats [123]. AP-1 activity was higher in dystrophin-deficient diaphragm, which was further 
augmented by mechanical stretch. This mechanical stretch-induced activation of AP-1 was 
compromised by pre-treatment of muscle fibers with PD98059 (a MEK inhibitor) indicating that 
phosphorylation is involved [124]. A more recent study showed that Fra-2 is expressed in both 
reserve and satellite cell populations of skeletal muscle, implicating a possible role in skeletal 
muscle regeneration, though the mechanisms involved are not yet clear [5]. 
Furthermore, global analysis of MyoD and MEF2 target genes in skeletal muscle reported that 
AP-1 binding sites are enriched in neighbouring sequences, suggesting AP-1 may be intrinsically 
connected with the myogenic regulators and possibly more involved in skeletal muscle regulation 
than previously anticipated [125,126]. 
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Skeletal Muscle regeneration 
 
Skeletal muscle constitutes 40%-50% of the adult human body mass, allowing locomotion and 
providing form, support and stability to the body [127]. Under normal biological conditions, adult 
skeletal muscle mass is relatively stable due to its robust regeneration capacity allowing 
maintenance and repair following injury [128–130]. Skeletal muscle regeneration is a highly 
orchestrated process mediated mainly by satellite cells, although other cells lying outside the basal 
lamina may also contribute to the regeneration process [131,132]. Skeletal muscle regeneration is 
accompanied by the activation of various cellular responses, regulated by multiple signalling 
pathways.   
 
2.1 Satellite cells 
 
    The satellite cell, since its identification by electron microscopy in 1961, has been the main 
focus of the skeletal muscle regeneration field. The presence of satellite cells was first detected in 
frog muscle, immediately followed by its confirmation in rat muscle [131,133]. Anatomically, 
those undifferentiated mononuclear cells located between the basal lamina and sarcolemma of 
skeletal muscle fibers [131] (Figure 4). Morphologically, satellite cells have a relatively high 
nuclear-to-cytoplasmic ratio, less organelle content, and a more compact nucleus compared with 
adjacent fiber myonuclei. These features are consistent with the finding that satellite cells are 
mitotically quiescent and transcriptionally less active than myonuclei under normal physiological 
conditions [134]. Satellite cells were later detected by phase-contrast microscopy on single 
myofiber explants base on their unique location [135]. Now, satellite cells can also be detected by 
fluorescence microscopy using specific biomarker. The most commonly used marker is the paired 
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domain transcription factor 7 (Pax7), which is specifically expressed in all quiescent and 
proliferating satellite cells of adult skeletal muscle [136,137]. Pax7 was shown to be critical for 
satellite cell specification and cell fate [138]. Other frequently used markers includes Pax3 [139], 
myogenic regulatory factor Myf5 [140], tyrosine receptor kinase c-Met [141], cell surface 
attachment receptor α7-intergin [142,143], transmembrane heparan sulfate proteoglycan 
syndecan-3 and syndecan-4 [144]. Practically, satellite cells are identified using combinations of 
the markers mentioned above, considering some of them are also expressed in other cell types 
within skeletal muscle.  
 
Figure 4: Anatomical location of satellite cells. Anatomically, satellite cells locate between the basal lamina and 
sarcolemma of skeletal muscle fibers. 
 
    Satellite cells together with all the other myogenic cell lineages share a common somitic origin, 
as suggested in early experiments using quail-chick chimeras [145]. Later evidences further 
suggested that adult satellite cells originate from the dermomyotome, an epithelial structure formed 
on the dorsal part of the somite [146–149]. Though another study suggested that the embryonic 
dorsal aorta can also give rise to adult satellite cells during fetal and postnatal muscle development 
[150]. The majority of skeletal muscle in vertebrates originates from somites with the exception 
of head muscles. Not surprisingly, different from satellite cells of trunk and limb muscles, adult 
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satellite cells of the various head muscles originate from their corresponding embryonic muscles 
[151]. 
 
    Satellite cells are a heterogeneous population in terms of their gene expression profile and cell 
surface markers. All satellite cells express Pax7, but only a subset of satellite cells expresses Pax3, 
the paralog of Pax7 [152,153]. Though Pax3 and Pax7 have overlapping functions, it was shown 
that Pax3 cannot replace the anti-apoptotic function of Pax7 in adult muscle progenitor cells [153]. 
Immunofluorescence staining revealed that expression of CD34 and Myf5 are not present in a 
subpopulation of quiescent adult skeletal muscle satellite cells [154]. MyoD, Myogenin, and c-
Met expression were also shown to be different among human skeletal muscle satellite cells, 
indicating their heterogeneity [155]. As mentioned previously, satellite cell origins of head muscle 
and body muscle are different. Consistent with this notion, two independent studies showed that 
satellite cells from head or body muscles express different molecular markers [151,156].  
    The heterogeneity of satellite cells is also reflected in their differentiation potential. Early 
studies using continuous infusion of bromodeoxyuridine (BrdU) labeling of satellite cells in vivo 
identified two distinct satellite cell populations, the responsive population and the reserve 
population [157]. It was found that the responsive population divides faster and acquires a 
proliferative fate, while the reserve population divides slower, suggesting a quiescent fate [157]. 
In agreement with this finding, a recent study showed that slow-dividing satellite cells retain long-
term self-renewal capability in adult muscle [158].  
    Increasing evidences have revealed that satellite cells are heterogenic in terms of their stemness, 
indicating that only a small population of satellite cells are true stem cells [159–161]. It was 
reported that Numb, an inhibitor of Notch, was localized asymmetrically in actively dividing cells 
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and inhibition of Notch signaling by Numb results in the commitment of progenitor cells to the 
myoblast cell fate [162]. In agreement with this finding, a study using Myf5-Cre and ROSA26-
YFP Cre-reporter alleles reported that Pax7+/Myf5+ cells are more prone to differentiation, while 
Pax7+/Myf5- cells acquire a quiescent and undifferentiated state, suggesting satellite cells are a 
heterogeneous population composed of stem cells and committed progenitors [160]. Interestingly, 
Myf5 was recently found to contribute to Pax7-dependent long-term maintenance of adult muscle 
stem cells [163].  
    In addition, the heterogeneity of satellite cells can also be reflected in their cell fate potential. 
Satellite cells were found to acquire an adipocyte fate when exposed to a high oxygen environment 
[164]. Muscle satellite cells also exhibit multi-potentiality which is a common stem cell feature 
and are able to acquire osteocyte and adipocyte phenotypes, depending on the extracellular cues 
[165]. Thus, satellite cells have the potential to differentiate to other cell linages, and this is largely 
determined by the culture environment.   
 
Satellite cells generally account for roughly 30% of the nuclei on myofibers in early postnatal 
muscle and this number is reduced to as low as 2% in adult muscles [166–168]. The distribution 
of satellite cells is denser at the ends of the myofibers, where the longitudinal growth of skeletal 
muscles takes place [169]. A few satellite cells can generate hundreds of satellite cells and restore 
regeneration capability, when transplanted into regeneration insufficient mice. Transplanted 
satellite cells can facilitate subsequent rounds of muscle regeneration, indicating that satellite cells 
are true muscle stem cells [170]. Stem cells are undifferentiated cells found in adult tissues that 
can give rise to functional progeny, while retaining the ability for self-renewal. Asymmetric 
division is a common function of stem cell self-renewal. Satellite cells, the muscle stem cells, are 
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undifferentiated cells in muscle tissue, they are mitotically quiescent under normal physiological 
conditions. Those cells may enter numerous rounds of proliferation in response to injury or stress 
to generate myoblasts that contribute to the repair of the existing damaged muscle fibres or 
generate new ones. Self-renewal through asymmetric division allows replenishment of the stem 
cell pool and generates more committed myogenic cells that contribute to skeletal muscle growth 
and regeneration. It has also been reported that satellite cells can undergo symmetric division, 
depending on the position of the daughter cells on the fiber [160](Figure 5). Non-canonical Wnt 
signaling is involved in the regulation of satellite cell self-renewal [171].  
 
Figure 5: Symmetric and asymmetric division of satellite cells.  Satellites cells are heterogeneous and can be 
divided into satellite stem cells and satellite myogenic cells. Satellite stem cells can divide symmetrically and 
asymmetrically. Satellite stem cells preferentially mediate satellite cell self-renewal and contribute to long-term 
muscle regeneration. While satellite myogenic cells preferentially differentiate following muscle injury. 
 
2.2 Satellite cell mediated skeletal muscle regeneration 
  
In mammalian species, adult skeletal muscle is a stable post-mitotic tissue with infrequent 
turnover of myonuclei [172]. Minor tears due to day-to-day wear can be repaired without causing 
cell death, inflammatory responses or involvement of satellite cells. However, when muscle is 
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subjected to severe injury, exposed to a toxic environment or pathological conditions, muscle 
repair is accompanied by the activation and proliferation of satellite cells, which are the main 
mediator of muscle regeneration in adulthood [173] (Figure 6).  
 
Figure 6: Satellite cell mediated muscle regeneration in response to muscle injury. In response to muscle injury, 
satellite cells become activated and proliferate. Some of the satellite cells will repopulate the satellite cell pool via 
self-renewal. Proliferating satellite cells will migrate to the damaged region and fuse with the existing myofiber to 
repair or fuse with each other to generate new myofibers.  In the regenerating myofiber, the newly fused myonuclei 
are centred, but will later migrate and assume a more peripheral location. 
 
Muscle regeneration shares similarities with muscle development during embryogenesis. In 
embryogenesis, all skeletal muscles are derived from mesodermal precursor cells and share somitic 
origin, except head muscles [139].  Study has shown that expression of Pax3 and Pax7 genes play 
an important role in specifying the satellite cell lineage of precursor cells [174]. Interestingly, Pax3 
and Pax7 are co-expressed in most of the myotomal cells of the somite indicating their involvement 
during embryogenesis [175]. Pax3 is required for the migration of muscle precursor cells from the 
somite, while Pax7 is involved in the specification of muscle precursor cells [176]. During 
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development, up-regulation of MyoD and Myf5, the basic helix-loop-helix transcriptional 
activators of the myogenic regulatory factor family (MRF), is required for the specification of 
precursor cells to the myogenic lineage. MyoD:Myf5 double knockout mice displayed a total loss 
of skeletal muscle [177,178]. The myogenic cells expressing Myf5 and MyoD are termed 
myoblasts [175]. Following up-regulation of Myogenin and MRF4, the secondary MRFs, the 
terminal differentiation of those myoblasts into myocytes occurs, which leads to the expression of 
late differentiation markers, such as myosin heavy chain (MyHC) and muscle creatine kinase 
(MCK). Subsequently, those mono-nucleated myocytes fuse with each other to form multi-
nucleated myotubes, which mature into contracting muscle fibers after innervation. Genome-wide 
loss of function study using CRISPER revealed that myomixer, a fusogenic micropeptide, is 
essential for fusion and muscle formation during embryogeniesis [179]. During the late stages of 
embryogenesis, a small population of those myogenic precursor cells maintain or resume the 
expression of Pax7 and escape from the differentiation pathway. Those cells are quiescent and 
mono-nucleated, anatomically associate closely with myofibers forming the satellite cell pool [180] 
(Figure 7). 
 
Figure 7: Model of embryonic skeletal muscle formation. Pax7 is required for the specification of myogenic lineage, 
while Pax3 contributes to myogenic cell expansion. MyoD and Myf5 induction by Pax7 commit cells into myogenic 
lineage and subsequently activate the expression of Myogenin and MRF4, directing progression of myogenesis and 
terminal differentiation. Finally, myocytes fusion generates multinucleated myotubes. Meantime, a distinct population, 
satellite cells, escape from fusion and remain in a quiescent undifferentiated state.  
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    Skeletal muscle regeneration, like skeletal muscle development, is a highly orchestrated process 
although there are some contextual differences in the two processes. Muscle regeneration begins 
with necrosis in the damaged muscle fibers, myofiber necrosis subsequently induces inflammatory 
responses [181]. Following this, muscle regeneration involves activation, differentiation and self-
renewal of satellite cells, as well as the maturation and remodeling of newly formed or repaired 
myofibers. As mention earlier, muscle regeneration shares similarities with embryonic myogenesis. 
This process recapitulates muscle development during embryogenesis in many but not all respects.  
    Under normal conditions, satellite cells are mitotically quiescent, those cells express Pax7 but 
not MyoD or Myogenin [140]. Interestingly, Myf5 expression was detected in the majority of 
quiescent satellite cells, indicating their commitment to the myogenic lineage [154]. Upon injury, 
satellite cells will be activated and start proliferating, and this is not restricted to the site of muscle 
injury. Studies have shown that localized damage at any site of a muscle fiber is able to activate 
all the satellite cells along the same myofiber, and migration of these satellite cells to the damaged 
site to facilitate regeneration [182]. In agreement with this finding, it was observed that activated 
satellites cells can migrate between myofibers and even across muscles during muscle growth and 
regeneration [183–185]. The c-Met receptor is essential for the migration of activated satellite cells 
into the limb bud [186]. By FACS analysis, muscle CD31(-) CD45(-) side population cells 
facilitate muscle regeneration by stimulating proliferation and migration of myoblasts [187]. CD34 
can promote satellite cell motility and entry into proliferation to facilitate efficient skeletal muscle 
regeneration [188]. In addition, it was found that BRE facilitates skeletal muscle regeneration by 
promoting satellite cell motility [189].  
    Activated satellite cells start expressing muscle regulatory factors, MyoD and Myf5, which are 
followed by the expression of desmin and Myogenin [190,191]. However, MyoD expression does 
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not necessarily promote commitment to differentiation. Several studies has shown that some 
Pax7+/MyoD+ proliferating myoblasts can lose their MyoD expression and eventually go back to 
quiescence [192–194]. Pax7 overexpression has an inhibitory effect on MyoD in adult primary 
myoblasts. It has been proposed that that the ratio of Pax7 and MyoD activities is critical in 
determining satellite cell fate [195]. Satellite cells with a high ratio of Pax7 to MyoD remain in 
their quiescent state, whereas satellite cells with an intermediate ratio of Pax7 to MyoD are prone 
to proliferate, but not differentiate. Satellite cells with a low Pax7 to MyoD ratio initiate 
differentiation.  
    After sufficient rounds of proliferation, the majority of satellite cells start expressing Myogenin 
and Myf6 [196]. Interestingly, Myogenin was found to inhibit Pax7 expression in adult primary 
myoblast, which further down-regulate Pax7 expression and promote differentiation [195]. MyoD 
and Myogenin can also facilitate differentiation by up-regulating a wide range of muscle-related 
genes, such as MEF2 and Myosins [125]. These cells exit from the cell cycle and begin to fuse to 
damaged myofibers or each other to repair existing myofibers or form new myofibers de novo 
[197]. Some fibers express embryonic forms of MyHC, indicating that fibers are formed de novo 
[198]. De novo formation of myofibers during muscle regeneration takes place in two steps. At 
first, individual differentiated myoblasts fuse to one another forming nascent myotubes with few 
nuclei. This is followed by additional myoblasts being incorporated into the existing nascent 
myotubes, generating a mature myofiber with more nuclei and increased size [199]. β1 integrins 
regulate myoblast fusion via regulation of the formation of a protein complex important for fusion 
[200]. A recent study showed that Myomaker, the only muscle-specific protein known to be 
absolutely essential for fusion of embryonic and adult myoblasts, is also essential for muscle 
regeneration [201]. When the majority of the activated satellite cells start to differentiate, a small 
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population returns to repopulate the satellite pool, re-establish its anatomical location and 
maintains its ability for future regeneration.  
 
2.3 Non-satellite cells with muscle regeneration potential 
 
    Satellite cells are the main mediator of skeletal muscle regeneration. However, increasing 
evidences revealed that non-satellite can also contribute to muscle regeneration.  
    The myogenic potential of bone marrow cells has been investigated for almost two decades. 
Early study found that bone marrow-derived cells can migrate into damaged muscle areas and 
undergo myogenic differentiation, suggesting the participation of bone marrow-derived cells in 
the regeneration of the damaged fibers [202]. Bone marrow was shown to assume a muscle satellite 
cell fate and participate in muscle regeneration after muscle damage [203]. This study also revealed 
that fetal liver cells have the same potential as bone marrow cell with respect to their involvement 
in muscle regeneration [203]. In agreement with those findings, a  recent study also revealed that 
bone marrow-derived mesenchymal stem cells injection can improve muscle regeneration and 
increase muscle contractile function [204].  
    Side population cells are a subset of Sca-1(+)cells first found in bone marrow cells, they are 
characterized by their exclusion of dyes such as Hoechst33342 and Rhodamine 123 [205]. Those 
cells found in the skeletal muscle are termed muscle side population cells, they have been found 
to regenerate muscle fibers [206]. Muscle side population cells are heterogenic and can be 
differentiated by cell surface markers [149,207]. Muscle CD45(+) side population cells isolated 
from adult mouse can be induced to differentiate into myogenic cells with forced Pax7 expression 
or activation of Wnt signalling [208,209]. Muscle CD31(-) CD45(-)side population can contribute 
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to new fibres post injury [210]. In agreement with this finding, this subset has been shown to 
promote muscle regeneration by stimulating proliferation and migration of myoblasts [187]. 
Recent study found that the progeny of muscle side population cells expressing Abcg2 contributes 
to regenerated myofibers after injury [211]. 
    PW1+ interstitial cells (PICs), a subset of interstitial cells, can differentiate into skeletal muscle 
after isolation from both young and adult mice [212]. PICs are myogenic in vitro and can 
efficiently contribute to skeletal muscle regeneration in vivo. Those cells can also give rise to 
satellite cells and PICs [213]. Recent study also revealed that PICs can generate skeletal muscle 
and self-renewal both in vivo and in vitro [214]. 
Muscle-derived stem cells (MDSCs), mesoangioblasts and pericytes are all multipotent, they 
have been shown to display myogenic potential and facilitate regeneration following injury. 
MDSCs has been shown to contribute to regenerated myofibers and incorporate into the satellite 
cell niche in transplantation experiments [215]. Mesoangioblasts are highly proliferative when 
cultured in vitro, and can give rise to skeletal muscle following transplantation [216]. Pericytes of 
human skeletal muscle are found to be myogenic precursors distinct from satellite cells, and can 
generate numerous myofibers [217]. Recent study also found that pericytes contribute to successful 
muscle regeneration by balancing between myogenic and non-myogenic cells, that are activated 
by type-1 and type-2 pericytes respectively [218].  
 
2.4 Regulation of skeletal muscle regeneration 
 
   Regulation of skeletal muscle regeneration following injury is fine-tuned process, which 
involves the coordination among a variety of secreted factors and multiple signalling pathways. 
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The microenvironment, including the extracellular matrix, also affects all aspects of regeneration 
(Figure 8). 
 
 
Figure 8: Schematic of skeletal muscle regeneration regulation. Skeletal muscle regeneration is under the 
regulation of various secreted factors, multiple signalling pathways and ECM.  
 
    Hepatocyte growth factor/scatter (HGF/SF) factor is one of the earliest secreted growth factors 
studied in muscle regeneration. Its cell surface receptor c-Met are found on both quiescent and 
activated satellite cells [219]. HGF/SF was found to activate quiescent skeletal muscle satellite 
cells via binding to c-Met in vitro [141]. HGF is present in muscle and can be released and bound 
to the extracellular matrix upon injury, and has the ability to activate quiescent satellite cells in 
vivo [220].  HGF/SF is the only known growth factor that activates quiescent satellite cells in 
skeletal muscle. It was found that HGF/SF can act directly on primary muscle cells to block 
differentiation, while promoting myoblast proliferation through synergy with factors in damaged 
muscle both in vitro and in vivo, indicating regeneration is not only regulated by myoblast number 
[221]. In this study, they also proposed that HGF inhibits the differentiation of myogenic precursor 
26 
 
cells probably by regulating Twist protein and p27 [221].  The dual function of HGF/SF in 
promoting proliferation and blocking differentiation involves activation of MAPK/ERK and 
phosphoinositide 3'-kinase (PI3K) pathways[222]. In addition, it was found that HGF/SF is 
expressed in cultured satellite cells, and that endogenous HGF/SF from satellite cells can act in an 
autocrine fashion. In this study, they proposed that direct administration of HGF/SF into damaged 
muscle may provide a useful approach for facilitating muscle repair, considering that HGF/SF 
plays a pivotal role in satellite cell activation [223].  
    Fibroblast growth factors (FGFs) are a large family of cytokines, involved in regulating many 
critical biological processes, including skeletal muscle development [224,225]. Accumulating 
evidences revealed that FGFs also play important roles in skeletal muscle regeneration. mRNA of  
FGF1, FGF2, FGF4, and FGF6 are detected in satellite cells,  and  has been shown to stimulate 
expansion of cultured satellite cells [226–228]. As a satellite cell mitogen, FGF2 was found to 
permit satellite cell proliferation by repressing myogenesis [229,230]. FGF-6(-/-) mutant mice 
show a severe regeneration defect following injury, possibly due to insufficient activation of 
satellite cells [231]. In contrast, it was reported that no skeletal muscle phenotypes were observed 
in FGF6-null mice [232]. However, injection of FGF6 was found to accelerate regeneration of the 
soleus muscle in adult mice [233].  A study using  FGF6-null mice showed that FGF6 regulates 
muscle differentiation through a calcineurin-dependent pathway in regenerating soleus of adult 
mice [234]. Most recently, FGF was found to regulate the early steps of dedifferentiation during 
skeletal muscle regeneration in adult zebrafish [235]. In this study, they also showed that inhibition 
of MEK activity with U0126 mimicked the phenotype of the FGF receptor inhibition, also 
activated ERK (p-ERK) was detected in injured muscles, suggesting FGF signaling in regenerating 
myocytes involves the MAPK/ERK pathway [235]. 
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    Insulin-like growth factors (IGFs) are known to play important roles in controlling the growth 
and differentiation of skeletal muscle [236]. Recently, the importance of IGFs during muscle repair 
has become more apparent. IGFs can function in endocrine, autocrine, and paracrine fashions to 
promote satellite cell proliferation and differentiation [237]. Those process are all mediated by 
IGF-I binding to the IGF-I receptor (IGF1R), which is a ligand-activated receptor tyrosine kinase. 
IGF-1 and IGF-1 receptors are found to be induced by various types of exercise in skeletal muscles 
[238–240]. Targeted expression of IGF-1 transgene to skeletal muscle was shown to promote 
muscle regeneration, indicated by faster recovery of muscle mass [241]. Local expression of IGF-
1 was found to accelerate muscle regeneration by rapidly modulating inflammatory response and 
reducing fibrosis and creating a qualitatively environment for more efficient muscle regeneration 
[242]. In agreement with those findings, overexpression of IGF-1 was reported to attenuate skeletal 
muscle damage and improve muscle regeneration and force recovery in soleus muscle [243]. In 
addition, conditional deletion of the IGF-1 gene specifically in mouse myeloid cells  was shown 
to block the normal induction of local IGF-1 in damaged muscle, resulting in significantly 
compromised regeneration [244]. Activation of ERK signalling was implicated in the role of IGF-
1 in skeletal muscle regeneration. A study found that IGF1R upon binding by IGF-1 can activate 
ERK pathway, which in turn activates other protein kinases and several transcription factors 
involved in proliferation [245,246]. Interestingly, the activation of the Ras/Raf/ERK pathway was 
shown to be required for satellite cell proliferation [245].   
    Transforming growth factor-beta (TGFβ) is a small family of multifunctional cytokines, 
consisting of TGFβ1, β2 and β3 and myostatin [247]. Accumulating evidence has indicated that 
they play important roles in skeletal muscle regeneration. TGFβ was revealed to inhibit skeletal 
muscle satellite cell differentiation in cultured rat satellite cells, and this inhibiting effect of TGFβ 
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on satellite cells is reversible [221]. Myostatin, a member of TGFβ family, was found to signal 
satellite cell quiescence and negatively regulates satellite cell self-renewal [248]. In this study, 
they showed that myostatin-deficient mice have more activated satellite cells compared with wild 
type. In contrast, addition of myostatin to myofiber explant cultures inhibits satellite cell activation 
[248]. Further investigation reported that myostatin signals through Pax7 to regulate satellite cell 
self-renewal [249].  The authors showed that myostatin can increase Pax7 expression level through 
ERK signaling pathway to help maintaining satellite cell quiescence [249]. In addition,  blockage 
of TGFβ in old, injured muscle restores satellite cell mediated muscle regeneration in vivo [250]. 
Also pharmacological inhibition of myostatin/TGF-β receptor/pSmad3 signaling rescues muscle 
regenerative responses in mouse model of type 1 diabetes [251]. A gene profiling analysis of in 
vivo quiescent and activated muscle satellite cells revealed that TGFβ is highly expressed in 
quiescent satellite cells, suggesting it may be more involved in muscle regeneration than 
previously anticipated [252]. Another TGFβ family member GDF11, sharing 90% homology with 
myostatin, was recently shown to increase expression with age and inhibits skeletal muscle 
regeneration [253,254]. 
    Other secreted factors that are also involved in skeletal muscle regeneration including 
Interleukin-6 (IL-6), Leukemia inhibitor factor (LIF), Tumor necrosis factor-α (TNFα) and 
Platelet-derived growth factor (PDGF). IL-6 was shown to be an essential regulator of satellite 
cell-mediated skeletal muscle hypertrophy [255]. The authors found that genetic loss of IL-6 blunts 
muscle hypertrophy in vivo. Also treatment with IL-6 promotes satellite cell proliferation via 
regulation of the cell-cycle-associated genes cyclin D1 and c-myc and STAT3 activation [255]. 
LIF was found to enhance regeneration in skeletal muscles after myoblast transplantation by 
increasing the number of dystrophin expressing fibers [256]. Study found that TNFα expression 
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was induced in cardiotoxin-injured soleus over the course of regeneration and it regulates muscle 
regeneration by activating p38 MAPK [257]. A most recent study revealed that PDGF-BB plays a 
protective role in muscular dystrophies by enhancing muscle regeneration through activation of 
satellite cell proliferation and migration [258].    
    Wnt signaling plays critical roles in many biological processes, including cell proliferation, cell 
fate determination, cell adhesion, cell polarity and morphology [259]. More and more studies have 
been revealing its implications in skeletal muscle regeneration. Canonical Wnt signaling pathway, 
also known as the Wnt/β-catenin pathway, was found to induce the myogenic specification of 
resident CD45(+) adult stem cells during muscle regeneration, suggesting a positive role in muscle 
regeneration [209]. In agreement with this finding, study also showed that canonical Wnt 
signalling induces satellite-cell proliferation during adult skeletal muscle regeneration [260]. 
Wnt/β-catenin pathway was recently revealed to regulate satellite cell myogenic potential through 
follistatin signalling [261]. In this study, the authors showed that the Wnt/β-catenin pathway 
induces follistatin expression in myoblasts and promotes myoblast fusion, and ectopic activation 
of the Wnt/β-catenin pathway in vivo promoted premature differentiation during muscle 
regeneration following injury [261]. In addition, a study using both in vivo and in vitro approaches 
found that the Wnt/β-catenin pathway in muscle progenitor cells regulates skeletal muscle 
regeneration [262]. In this study, they showed that β-catenin deficient myoblasts exhibit delayed 
differentiation, whereas myoblasts with constitutively active β-catenin undergo precocious growth 
arrest and differentiation [262]. In contrast, another study reported that increased Wnt signaling 
during aging converts satellite cells from a myogenic lineage to a fibrogenic one in aged mice, 
resulting in compromised muscle regeneration capacity. And this lineage conversion can be 
suppressed by inhibitors of canonical Wnt signalling [263]. Those conflicting findings are possibly 
30 
 
due to the different systems were being used to conduct experiments. Non-canonical Wnt 
signalling pathway, also known as the Wnt/PCP (planar cell polarization) pathway, is also involved 
in skeletal muscle regeneration. Activation of Wnt/PCP pathway by Wnt7a was found to drive the 
symmetric expansion of satellite cells, without any effect on the growth or differentiation of 
myoblasts, suggesting its role in regulating the muscle regenerative potential possibly via control 
of the homeostatic level of satellite stem cells [171].  
    Sphingolipids are a large group of naturally occurring glycolipids. They have important roles as 
signalling and regulatory molecules in cell proliferation, migration, death, and senescence 
[264,265]. Increasing evidences revealed that sphingolipids, particularly sphingosine-1-phosphate 
(S1P), also play important roles in skeletal muscle regeneration. A study has found that entry of 
muscle satellite cells into the cell cycle requires sphingolipid signaling, and inhibition of 
sphingolipid signaling reduces the number of satellite cells able to proliferate in response to 
mitogen stimulation both in vitro and in vivo [266]. Administration of S1P following myotoxic 
injury causes a significant increase of the regenerating fibers in both rat and mouse, and 
administration of anti-S1P antibody attenuates fiber growth [267]. S1P was also found to positively 
influence satellite cell proliferation and migration, facilitating the recruitment of satellite cells to 
the site of muscle damage [268]. In addition, S1P was reported to enhance satellite cell activation 
in dystrophic muscles by repression of cell cycle inhibitors via S1PR2/STAT3-dependent 
signaling [269]. S1P recently was shown to be involved in mediating epidermal growth factor-
induced satellite cell activation, and this activation is S1P receptor dependant [270]. Interestingly, 
Ras/Raf/ERK pathway was found to be activated by S1P by transactivating epidermal growth 
factor receptor in rat-2 cells [271]. As mentioned earlier, the activation of the Ras/Raf/ERK 
pathway is required for satellite cell proliferation [245].  
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    The Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling 
pathway is also involved in skeletal muscle regeneration. Inhibition of JAK-STAT signaling was 
found to stimulate adult satellite cell function, indicated by  pharmacological inhibition of Jak2 
and Stat3 activity can promote symmetric expansion of satellite cells both in vitro and in vivo [272]. 
In agreement with this finding, transient Stat3 inhibition was found to promote satellite cell 
expansion and enhanced tissue repair in both aged and dystrophic muscle [273]. In contrast, the 
same study also found that IL-6-activated Stat3 signaling was shown to promote satellite myogenic 
lineage progression through myogenic differentiation 1 (Myod1) regulation. Conditional depletion 
of Stat3 in Pax7-expressing satellite cells stimulates satellite cell proliferation, but compromised 
myogenic differentiation due to inhibition of fusion to regenerating myofibers [273]. A recent 
study found that loss of Stat3 in MuSCs impairs their proliferation and self-renewal upon injury, 
and loss of Stat3 in MuSCs of dystrophic mice leads to severe fibrosis and inflammation, which 
are detrimental to muscle regeneration [274]. 
    p38, a subgroup of the MAPKs, is involved in the regulation of multiple cellular processes, 
including senescence, apoptosis, cell-cycle arrest, RNA splicing and tumor formation [275,276]. 
Recent studies revealed that p38 is also involved in skeletal muscle regeneration. p38α/β MAPK 
was found to function as a molecular switch to activate the quiescent satellite cells [277]. The 
authors showed that p38α/β MAPK can reversibly regulate the quiescence of muscle satellite cells. 
Blockage of p38α/β MAPK promotes cell cycle withdrawal and prevents differentiation. 
Meantime insulating satellite cells from most external stimuli permits them to maintain a quiescent 
state [277]. Another study showed that genetic knockdown or pharmacological inhibition of p38α 
promotes Pax7 expression and expansion of satellite cells, and this effect is reversible [278]. 
Attenuation of p38-mediated miR-1/133 expression by FGF2 was found to facilitate myoblast 
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proliferation during the early stage of muscle regeneration [279]. Asymmetric activation of p38α/β 
MAPK by Par complex induces MyoD in only one daughter cell, which commits to myogenesis. 
While the other daughter cell adopts a quiescent satellite cell phenotype, preserving the stem cell 
population for future maintenance and repair of skeletal muscle tissue [280]. Polar distribution of 
the Par complex orients the plane of division and reinforces differential daughter cell fates through 
downstream signaling pathways [281,282]. Self-renewal and p38 MAPK signaling are found to be 
impaired in aged satellite cells, and the subcellular localization, duration of signaling, and timing 
of p38αβ MAPK activation are implicated to be highly involved in satellite asymmetric division 
self-renewal [283]. 
    Sonic hedgehog (Shh) signalling was considered silent in post-natal life, though it plays crucial 
roles during embryonic development [284,285]. Increasing evidences revealed that Shh signalling 
is also involved in adult skeletal muscle regeneration. Shh pathway was found to regulate the cell 
fate of adult muscle satellite cells in mammals by acting as a proliferation and survival factor [286]. 
Shh signalling promotes proliferation and differentiation of adult muscle satellite cells, and Shh-
induced Akt phosphorylation is required for its promotive effects on muscle satellite cells [287]. 
Inhibition of Shh signalling was found to reduce the number of myogenic satellite cells at injured 
site due to insufficient up-regulation of IGF-1 and impaired activation of MRFs, Myf-5 and MyoD 
[288]. The authors also observed Shh inhibition results in muscle fibrosis, increased inflammatory 
reaction and compromised motor functional recovery after injury [288]. Recent study also showed 
that intramuscular therapy with a plasmid encoding the human Shh gene increases the regenerative 
potential of the injured muscle by promoting satellite cell proliferation. At the molecular level, 
Shh treatment was shown to increase IGF-1, which will further facilitate muscle regeneration [289].  
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    Other signalling pathways also involved in skeletal muscle regeneration includes the 
Angiotensin type 2 receptor (AT2R) signaling, Gαi2 signaling, bone morphogenetic protein (BMP) 
signalling and Notch signalling. AT2R signaling was shown to positively regulate myoblast 
differentiation and potentiates skeletal muscle regenerative potential via upregulation of phospho-
ERK1/2 [290]. Gαi2 signaling was found to be required for skeletal muscle regeneration, satellite 
cell proliferation and differentiation [291]. Recent study revealed that BMP signalling permits 
population expansion by preventing premature myogenic differentiation in muscle satellite cells 
[292]. The involvement of Notch signalling in muscle regeneration will be discussed in detail later.  
The extracellular matrix (ECM) is the non-cellular component consisting of collagens, elastin, 
fibronectin, laminin, and proteoglycans. The ECM provides essential physical scaffolding for the 
cellular components,  also initiates crucial cues that are required for many cellular processes 
[293,294]. The ECM of skeletal muscle is composed of the interstitial matrix and the basement 
membrane. Upon injury, the damaged basement membrane hull is left behind where it can function 
as a scaffold to direct the fusion of newly generated myofiber [295]. ECM protein syndecan-3 and 
syndecan-4, members of cell-surface transmembrane heparan sulfate proteoglycans (HSPGs) 
family, specifically mark skeletal muscle satellite cells and are implicated in satellite cell 
maintenance and muscle regeneration. Inhibition of HSPGs sulfation with chlorate delays satellite 
cell proliferation due to altered MyoD expression, suggesting syndecan-3 and syndecan-4 sulfation 
is required for the progression of satellite cell myogenic program [144]. ECM was shown to 
provide instructive cues to satellite cells and instruct cell behavior during muscle regeneration 
[296]. Study also found that ECM protein collagen VI is a key component of the satellite cell niche 
and regulates satellite cell self-renewal and muscle regeneration [297]. This is demonstrated by 
lack of collagen causes impaired muscle regeneration and reduced satellite cell self-renewal after 
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injury. Also Collagen VI null muscles display significant decrease of stiffness, which results in 
compromised activity of wild-type satellite cells both in vitro and in vivo [297]. In agreement with 
this finding, it was observed that myotubes differentiate optimally on substrates with tissue-like 
stiffness, whereas either softer or stiffer gels greatly compromise their differentiation efficiency 
[298]. Loss of fibronectin in the ECM was found to affect the regenerative capacity of skeletal 
muscle in aged mice. The authors showed that fibronectin acts as a preferred adhesion substrate 
for satellite cells, and the loss of satellite cell adhesion to fibronectin in the ECM leads to 
compromised muscle regeneration [299]. Furthermore, ECM can act as reservoir for growth 
factors such as HGFs, FGFs, VEGFs, BMPs and TGF-β, which are inactive under normal 
condition due to binding by the ECM protein vitronectin, fibronectin, collagens and proteoglycans. 
On the other hand, proteins and proteoglycans of the ECM can also function as distributors of 
those growth factors during injury induced muscle regeneration. This is accompanied by 
remodeling of the ECM, which is mediated by metalloproteinases [300].  
 
Notch signalling 
 
Notch is a transmembrane receptor that is present in all animal species studied to date. It 
regulates local cell-cell communication and mediates cell fate determination [301]. The signalling 
cascade coordinated by Notch receptor, namely the Notch signaling pathway is highly conserved 
among organisms [302,303]. It was first discovered in 1917 by geneticist Thomas Hunt Morgan 
and his colleagues when they noticed notches in the wing blades of fruit flies [304].  Since its 
discovery, Notch signalling has been shown to play critical roles in many aspects of embryonic 
development, as well as differentiation, tissue homeostasis and regeneration [303,305].  
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3.1 Notch signalling ligands 
 
    Canonical Notch ligands are characterized by the presence of a DSL (Delta, Serrate, and Lag2) 
domain in their structure. And this DSL ligand family has been shown to induce the majority of 
Notch signaling [306,307]. In Drosophila melanogaster, there are two Notch DSL ligands, Delta 
and Serrate. In mammals, there are five Notch DSL ligands the Delta-like family (DLL1, DLL3 
and DLL4) and the Jagged family (Jagged 1 and 2) based on homology to Delta and Serrate in 
Drosophila melanogaster [303]. Notch DSL ligands are transmembrane proteins sharing a 
common modular arrangement in their extracellular domains, which contains varying numbers of 
Epidermal Growth Factor (EGF)-like repeats and a cysteine-rich N-terminal DSL domain (Figure 
9A). The DSL domain is present in all DSL ligands and evolutionarily conserved, and it is required 
for the interaction between Notch ligands and receptors. Serrate, Jagged 1 and Jagged 2 contain an 
additional cysteine-rich domain [308].  
    Unlike the activating canonical ligands that contain a DSL domain, non-canonical Notch ligands 
do not contain the DSL domain and comprise a group of structurally diverse proteins, including 
integral and glycosylphosphatidylinositol (GPI)-linked membrane proteins as well as some 
secreted proteins, which are implicated in the regulation of Notch receptor activity [309]. 
 
3.2 Notch signalling receptor 
 
Notch receptors, like Notch ligands, are also transmembrane proteins. Notably, they are large 
single-pass type I transmembrane proteins. There are one in Drosophila melanogaster (Notch), 
two in Caenorhabditis elegans (LIN-12 and GLP-1) and four Notch receptors in mammals 
(Notch1–4), and they have been conserved from invertebrates to humans [301,310,311]. Notch 
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receptors are also multi-domain proteins (Figure 9B). The Notch extracellular domain (NECD) is 
relatively large and consists of 29 to 36 EGF-like repeats, which are subjected to post-translational 
modification by a variety of glycans and have been implicated in the regulation of Notch function 
[312]. Earlier study has shown that the EGF-like repeats 11–12 are required and sufficient to 
mediate the interaction between Notch ligands and receptors [313]. Following the NECD is the 
negative regulatory region (NRR), which consists of the three-cysteine rich Lin–Notch repeats 
(LNRs) and a region that links to the transmembrane and intracellular fragment. Study has found 
that the NRR can block the access of metalloproteinases to the S2 cleavage site of Notch to prevent 
premature activation of the receptor [302,303,314]. The Notch intracellular domain (NICD) is 
composed of four distinct regions, the RBPJ-associated molecule (RAM) domain, the ankyrin 
(ANK) repeats, a transcriptional activation domain (TAD) and a C-terminal Pro-Glu-Ser-Thr 
(PEST) sequence. Two nuclear localization sequences (NLS) are flanking the ANK repeats.  The 
RAM and ANK domains are essential for the binding of NICD to CSL (CBF1, Suppressor of 
Hairless, Lag1) in the nucleus [315].  
 
3.3 Nuclear effectors of Notch signalling 
 
CSL (CBF-1/RBP-Jκ, Su(H), Lag-1), collectively named after the mammalian, Drosophila 
melanogaster, and Caenorhabditis elegans orthologous proteins, respectively, is a DNA binding 
transcription factor. As the key transducer of the Notch signalling, CSL is required for both 
activation and repression of Notch target genes.  CSL shares similarity with the Rel transcription 
factor family. In comparison to Rel, CSL has an extra insertion of a central modified β-trefoil 
domain (BTD) between the two Rel-homology regions (RHR-N, RHR-C) [316] (Figure 9C). The 
RHR-N and BTD domains are the main domains mediating DNA and CSL interaction. There is 
37 
 
hydrophobic pocket within the BTD domain that is thought to mediate the interaction between 
CSL and NICD. In addition, beside CSL, the co-activator Mastermind (Mam) is also required to 
activate transcription. Unlike Notch ligands and receptors, Mam proteins from different species 
share little sequence homology except an extended α-helical domain formed in the N-terminal 
region. This extended α-helical domain contacts the RHR-N and RHR-C domains of CSL and the 
ANK domain of NICD in a trimeric complex [317,318].  
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Figure 9: Schematics of Notch pathway components. A: Notch ligand contains DSL (Delta/Serrate/LAG-2), EGF-
like repeats and a cysteine-rich (CYS-rich) domain, followed by single transmembrane-spanning segment (TM). B: 
Extracellularly, Notch receptor possesses multiple EGF-like repeats followed by the NRR, which consists of the LNR 
(Lin12-Notch Repeats) and the HD (Heterodimerization Domain). There is a single transmembrane-spanning segment 
(TM) following NRR. Intracellularly, Notch receptor contains RAM (RBP-J Associated Molecule) and ANK (ankyrin 
repeats) domains as well as TAD and PEST (proline, glutamate, serine, and threonine) domains. NLS (Nuclear 
localization signal) and S1, S2, and S3 cleavage sites are indicated. C: CSL (CBF1/RBP-J, Su(H), Lag1) consists of 
three domains: NTD (amino-terminal domains), BTD (β-trefoil domain), and CTD (carboxy-terminal domains). The 
NTD and CTD structurally resemble the RHR-N and RHR-C (Rel-homology region) domains, respectively. 
 
3.4 The core of Notch signalling pathway 
  
Notch signaling links the fate of one cell with its neighboring cell through physical interactions 
between the Notch receptor and the membrane-bound ligands that are differentially expressed in 
the apposing cell.  And this is mediated by a successive proteolytic cleavage events which are 
described in detail in the following section (Figure 10).  
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Figure 10: The core Notch signalling pathway. Binding of the Notch ligand on one cell to the Notch receptor on 
another cell results in two proteolytic cleavages of the receptor, generating a substrate for S3 cleavage by the γ-
secretase complex. This proteolytic cleavage results in the release of the Notch intracellular domain (NICD), which 
translocates to the nucleus and interacts with the DNA-binding CSL (CBF1, Su(H) and LAG-1) protein. The co-
activator Mastermind (Mam) is subsequently recruited to the CSL complex, replacing the co-repressors (CoR), and 
drive Notch target gene expression. 
 
    Newly synthesized Notch receptors are proteolytically cleaved in the NECD at the Golgi 
complex (at site S1) during their transport to the cell surface by a Furin-like protease, generating 
a functional heterodimeric Notch receptor located to the cell surface [319]. During Notch receptor 
synthesis and secretion, the NECD undergoes O-linked glycosylation which facilitates the proper 
folding of the Notch receptor and the interaction with its ligand DSL [312].  
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Notch signaling is initiated by ligand-receptor direct interaction between signal-sending cell and 
signal-receiving cell [302,303]. Ligand–receptor binding presumably induces a conformational 
change within the Notch receptors to expose the S2 cleavage site for proteolysis, which in turn 
facilitates the second NECD cleavage (at site 2) mediated by a metalloproteinase ADAM. This 
results in the shedding of most of the receptors external domain, which is trans-endocytosed into 
the signal-sending cell together with its ligand [320]. After shedding of the extracellular domain, 
Notch receptor becomes a γ-secretase substrate, which is further cleaved (at site 3) within the 
Notch receptor transmembrane domain by γ-secretase, a multiprotein complex containing 
Presenilin [321,322]. This then liberates the NICD from the membrane.  
    The liberated NICD translocates to the nucleus and heterodimerizes with the DNA binding 
transcription factor CSL, forming a short-lived nuclear transcription complex. Once bound to CSL, 
NICD recruits other transcriptional co-activators including Mam proteins (MAML1-3) to drive the 
expression of Notch target genes, such as members of the Hairy enhancer of split (Hes) or Hairy 
related (Hey or Hrt) genes [302,303]. In the absence of NICD, CSL forms complexes with a wide 
range of co-repressors to suppress Notch target genes transcription [302,303].  
 
3.5 Function of Notch signalling 
 
    In general, trans-interactions between ligand and receptor that are expressed in apposing cells 
define activating events, while cis-interactions between ligand and receptor that are expressed in 
the same cell are inhibitory in nature [323,324]. Almost all tissues are affected by cell fate choices 
that are regulated by Notch signaling. The exact outcome of Notch signalling is highly context-
dependent.  
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    The most popular mode of Notch signalling is lateral inhibition, which describes the 
mechanisms cells use to adopt one particular cell fate while influencing the fate of its neighbouring 
cell [325]. Early evidence for this mechanism came from studies in the grasshopper embryo, where 
laser ablation of an emerging neuroblast caused a neighbouring cell, normally fated to remain 
epidermal, to instead adopt a neuroblast cell fate [326]. The classical demonstration of lateral 
inhibition is in the case of neuroblast differentiation within the neurogenic region of the Drosophila 
embryo. In this case, a cell that is fated to become a neuroblast inhibits its immediate neighbours 
from adopting the same fate [326,327]. During development, many other positional cues act in 
concert with lateral inhibition to mediate the specification of different cell types. 
    Another mode of Notch signaling in cell-fated decision has been documented during the 
differentiation of the Drosophila melanogaster sensory organ precursors (SOP) lineage, where the 
analysis of the SOP cell lineage gave new insight into the role of Notch signaling in binary cell-
fate decisions. In this case Notch helps making lineage decisions by mediating the asymmetrical 
segregation of specific lineages regulators in the otherwise developmentally equivalent daughter 
cells, leading to asymmetric activation of Notch signaling, where one of the daughter cells 
becomes the signal-sending cell, whereas the other cell becomes the signal-receiving cell. Studies 
have shown that Numb and Neuralized (Neur) E3-ligase are asymmetrically inherited by the two 
daughter cells and subsequently involved in decision making of the cells, implicating the role of 
Notch in asymmetrical division [328,329]. The progeny again uses the Notch pathway in a second 
round of cell division to establish different cell fates [302]. 
    In addition, Notch signaling is also crucial in the specification of borders between cellular fields 
by inducing intrinsic differences between two adjacent populations of cells, which can translate 
into distinct signalling populations. Two examples of the intrinsic differences induced by Notch 
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are restricted expression of ligands and Fringe glycosyl transferases, the later results in 
modifications to Notch and alters its capability to respond to ligands, together they will contribute 
to border specification [330–332].  
    Notch function has its longest history in the central nervous system (CNS) and is well known 
as a master regulator of neural stem cells (NSCs) and neural development. Early study showed that 
Notch1 is distributed asymmetrically in proliferating NSCs, with Notchl inherited selectively by 
one daughter cell that is fated to form new neuron, while the other daughter cell without Notch1 
expression remains quiescent and maintains the neuron progenitor pool [333]. Differential 
expression of mammalian Numb, Numblike and Notch1 was also found in dividing neuron 
progenitor cells during mouse cortical neurogenesis, suggesting its role in mediating cell-fate 
decision [334]. Notch signaling is found to be involved in the generation of neurons/glia from 
NSCs in a stepwise process. At first Notch signalling inhibits the neuronal fate while promoting 
the glial cell fate of dividing NSCs. However, in the following step, Notch signalling inhibits the 
differentiation of both neurons and oligodendrocytes, while promotes the differentiation of 
astrocytes [335]. Recent study also showed that the NSCs that undergo asymmetric cell divisions 
express Notch1, whereas those that undergo symmetric cell divisions do not, indicating Notch1 
expression is involved in initiating the switch between the symmetric to asymmetric cell divisions 
of NSCs [336]. Furthermore, Notch signalling is also required for neuronal migration in the 
Cerebral Cortex [337].  
    In addition, Notch signaling also plays important and complex roles in cell proliferation, cell 
differentiation and tumor formation, where it can play both positive and negative roles depending 
on the cellular context. Jagged1-induced Notch signaling was shown to promote the proliferation 
of multiple myeloma cells [338]. In consistent with this finding, Notch was found to maintain 
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blastema in a proliferative state and prevent differentiation during adult zebrafish fin regeneration 
[339]. Interestingly, Notch signalling was found to suppress the proliferation of early chondrogenic 
cells, surprisingly also inhibits the differentiation of those cells at the same time [340]. While study 
in keratinocyte found that Notch signaling is a direct determinant of growth arrest and promotes 
the differentiation keratinocyte [341]. Considering those studies are conducted using different cell 
types, recent study revealed that Notch signalling can also have different effects on the same cell 
type. Study in heart regeneration revealed that suppression of Notch signaling negatively affects 
cardiac regeneration due to insufficient cardiomyocyte proliferation, whereas, hyperactivation of 
Notch signaling also inhibits cardiomyocyte proliferation and heart regeneration, suggesting the 
dual role of Notch signalling in regulating of cell proliferation [342]. Notch signalling was first 
connected to cancer in 1991, TAN-1, the human homolog of the Drosophila notch gene, is found 
mutated due to chromosomal translocations in T lymphoblastic neoplasms [343]. The association 
of Notch with tumours is further studied and well characterised in human T cell acute 
lymphoblastic leukaemia using gain-of-function Notch1 mutations [344]. On the contrast, Notch1 
was found to function as a tumor suppressor in mouse skin [345]. The developmental context of a 
cell appears to play major roles in dictating how activation of Notch signalling will affect the cell 
fate.  
Furthermore, Notch signaling has been shown to be critical for the generation, specification, 
proliferation, differentiation and maintenance of stem cells in almost every system examined, 
including the CNS mentioned earlier. Notch signalling mediated by Notch1 but not Notch2 is 
found to be essential for the generation of hematopoietic stem cells from endothelial cells [346]. 
In agreement with this finding, study also showed that Notch signalling is crucial for the formation 
of intra-embryonic hematopoietic cells [347]. Activated Notch signaling in human embryonic stem 
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cells was found to be required for embryonic lineage commitment [348]. Notch signaling is 
involved in modulating the proliferation and differentiation of intestinal crypt base columnar (CBC) 
stem cells. The authors observed that Notch directly targets the CBC cell to maintain stem cell 
activity. Suppression of Notch impairs CBC stem cell proliferation, leading to rapid CBC cell loss 
and precocious differentiation of epithelial progenitors into secretory cell types [349]. Notch 
pathway molecules are revealed to be essential for the maintenance, but not the generation, of 
mammalian neural stem cells (NSCs). The authors showed NSCs are generated independent of 
RBP- Jκ, a key molecule in Notch signaling. Inhibition of Notch signaling enhances both neuronal 
and glial differentiation in vitro, and overexpression of Notch1 suppresses the differentiation of 
both lineages [350]. Notch signalling has been shown to mediate cell fate specification of 
multipotent intestinal stem cells (ISCs) in Drosophila melanogaster.  The adult Drosophila midgut 
contains multipotent ISCs that can generate both enterocytes and enteroendocrine cells. ISCs with 
high level activated Notch signalling down-regulates the Notch signalling within their daughters 
and specify these daughters into enterocytes lineage. ISCs with low level or impaired Notch 
signaling specify their daughters to become enteroendocrine cells, suggesting that ISCs actively 
coordinate cell production with local tissue requirements to maintain homeostasis [351]. Recent 
study revealed that Notch1 and Notch2 together mediates intestinal stem cell homeostasis through 
regulating epithelial cell proliferation, cell fate determination during post-injury regeneration [352]. 
 
Notch signalling in skeletal muscle regeneration 
 
    As mentioned above, Notch signalling is involved in the regulation of stem cells in almost all 
systems studied. Stem cells in muscle are no exception. Accumulating evidences have revealed 
that Notch signaling plays several key roles in skeletal muscle regeneration [353]. Notch signaling 
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was reported to control satellite cell activation and cell fate determination during muscle 
regeneration upon injury. The authors found that Notch signalling is activated upon muscle injury, 
indicated by the upregulation of the Notch ligand Delta and NICD expression. Activation of Notch 
signalling also promotes the proliferation of satellite cells and the expansion of their progenies that 
contribute to regeneration. While inhibition of Notch signaling leads to the immediate commitment 
and differentiation of satellite cells and subsequently impairs muscle regeneration [162]. 
Interestingly, constitutive Notch activation was found to upregulate Pax7 expression and promotes 
the self-renewal of skeletal muscle satellite cells by inhibiting MyoD and myogenic differentiation, 
resulting in compromised muscle regeneration [354]. Earlier studies suggested that NICD can 
inhibit differentiation by directly interacting with MEF2C and blocking its transcriptional potential 
to activate myogenic genes [355]. Similarly, the Notch target Hey1 can also prevent differentiation 
of muscle progenitors by transcriptionally repressing key myogenic genes, including Myogenin 
and MEF2C [356]. In aged mice, skeletal muscle regeneration upon injury is compromised due to 
reduced satellite cells proliferation, resulting from insufficient activation of Notch signalling. 
Though the expression of Notch in satellite cells remains unchanged in aged mice compared with 
young mice. However, the induction of Notch ligand Delta in myofibers is no longer responsive 
to muscle injury, and thus diminished activation of Notch in aged muscle, suggesting that Notch 
signaling is a key determinant of muscle regenerative potential that declines with age [357].  
     From the findings mentioned above, it is obvious that activation of Notch signalling is crucial 
for the activation and proliferation of satellite cells. During muscle regeneration, inactivation of 
Notch signalling in proliferating precursor cells is required for their myogenic commitment and 
fusion [162]. Numb, a Notch signaling inhibitor that inhibits Notch signaling by inducing 
ubiquitination of the NICD, was shown to be involved in mediating this process [301]. Numb is 
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asymmetrically expressed in dividing progenitor cells, the daughter cell expresses Numb is fated 
to differentiate by activating the expression of Desmin, while the daughter without Numb 
expression remain proliferative [161,162]. 
    Notch signaling is also involved in the maintenance of cell quiescence in resting muscle. In adult 
homeostatic muscle, it was found that Notch-1, -2, and -3 as well as high levels of the Notch/RBP-
Jκ target genes Hes1 Hey1 and HeyL are expressed in quiescent satellite cells, indicating high 
level of Notch activity. Notch signaling was shown to be required to maintain the quiescent state 
of skeletal muscle stem cell. Conditional abrogation of Notch signalling by targeted deletion of 
RBP-Jκ leads to the spontaneous differentiation of muscle stem cells, thereby resulting in a severe 
depletion of the stem cell pool, indicating that satellite cells are sustained in a quiescent state by 
Notch activity [358,359]. In agreement with this notion, double knockout mice of Hey1 and HeyL, 
was found to have markedly reduced number of satellite cells, which is likely due to failure of 
satellite cells in remaining quiescent state [360]. Interestingly, in comparison to Notch1 mutants, 
Notch3-deficient mice have a seemingly opposite phenotype, with an abnormally increased 
number of quiescent satellite cells and hypertrophic regenerated muscle even after repetitive 
muscle injuries, indicating an antagonistic function with the other Notch receptors. Overexpression 
of Notch3 also activated the expression of Nrarp, a negative feedback regulator of Notch signaling, 
suggesting that Notch3 might act as a Notch1 repressor by activating Nrarp [361]. 
 
Cross-talk between Notch and other signalling pathways in skeletal muscle 
regeneration 
 
    Notch signaling also influences skeletal muscle regeneration through cooperation with other 
signaling pathways.  
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    BMP signaling was shown to induce the proliferation of satellite cells and block their premature 
differentiation [292]. In this context, BMP signaling promotes Notch-dependent activation of Hes1 
and Hey1 to inhibit differentiation of satellite cells, and the inhibitory effect can be restored by 
blocking Notch signaling [362].  
    TGF-β expresses at excessive level in old muscle, which leads to unusually high level of 
pSmad3 expression in satellite cells and subsequently affects their regenerative capacity. In this 
case, endogenous Notch and pSmad3 were found to antagonize each other in the control of 
satellite-cell proliferation. This is supported by the observation that activation of Notch blocks the 
TGF-β-dependent induction of the cyclin-dependent kinase (CDK) inhibitors p15, p16, p21 and 
p27, whereas inhibition of Notch induces them. In addition, Notch activity determines the binding 
of pSmad3 to the promoters of these negative regulators of cell-cycle progression in satellite cells 
[250]. 
    Crosstalk between Notch and Wnt signaling in satellite cells seems to regulate the transition 
from an undifferentiated to a differentiated state during muscle regeneration. Study has revealed 
that a temporal switch from Notch to Wnt signaling in muscle stem cells is necessary for muscle 
regeneration. The authors observed that activation of Wnt signaling in differentiating myoblasts 
antagonizes Notch signaling and facilitates terminal differentiation during muscle regeneration. 
This switch is also mediated by glycogen synthase kinase 3β (GSK3β). In addition, inhibition of 
Notch signaling in regenerating muscle leads to elevated level of Wnt activity and premature 
differentiation, suggesting the temporal crosstalk between Notch and Wnt is critical for proper 
proliferative expansion followed by differentiation during muscle regeneration [363]. 
    In summary, although much is known about the role of satellite cells in muscle maintenance and 
repair. Likewise, there is a huge amount of literature characterizing AP-1 function. However, to 
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date there are few studies addressing the role of AP-1 in satellite cells. Thus, in this dissertation, a 
number of studies were carried out to further delineate the role of AP-1 in muscle progenitor cells 
and satellite stem cells. 
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Statement of Purpose 
 
Skeletal muscle, as the indispensable motor of body movement, possesses a robust regeneration 
capability, which is mainly mediated by satellite cells. The identification and use of satellite cells 
have attracted considerable interest from scientists in the muscle regeneration field. Satellite cells, 
also known as muscle progenitor cells, possess numerous advantages for adult muscle regeneration 
study, such as easy identification, self-renewal, and myogenic differentiation potential, yet, to date, 
the exact mechanisms controlling satellite cell biology during skeletal muscle regeneration are still 
incomplete. This is mostly due to the fact that each phase of skeletal muscle regeneration is highly 
regulated by complex signaling pathways. Despite progress made in the past decades, many 
questions remain unresolved. Further understanding of the signalling pathways and cellular 
regulators involved in skeletal muscle regeneration at the molecular level may therefore pave the 
way for therapeutic strategies and clinical applications in contexts in which muscle health is 
compromised, such as during aging (sarcopenia), myopathic diseases (cachexia, DMD), or 
inactivity (atrophy).  
AP-1 has been documented as a versatile protein that is directly or indirectly involved in a 
variety of cellular processes. As a ubiquitously expressed transcription factor, it alters target gene 
expression in response to upstream signals upon its specific binding to its cognate DNA binding 
element, the TRE. Mutations to components of the AP-1 complex have profound effects on the 
cell, leading to a plethora of defects during vertebrate development. Previously, AP-1 has been 
implicated in playing a role in satellite cell biology by our group. These studies established a co-
localization of Fra-2/AP-1 and the satellite cell marker Pax7. Also ERK MAPK was shown to 
phosphorylate Fra-2/AP-1 and stabilizes its activity [5].  However, the precise role of AP-1 in 
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muscle progenitor cells requires further characterization. The studies undertaken here were 
therefore aimed at further characterizing the role and mechanism of AP-1 function in skeletal 
muscle progenitor cells. 
In our studies, we used C2C12 mouse myoblast cell line, primary mouse myoblasts and single 
fiber culture as models to study myogenesis and skeletal muscle regeneration.  
The C2C12 cell line is a subclone (produced by H. Blau, et al) of the mouse myoblast cell line 
established by D. Yaffe and O. Saxel from normal adult C3H mouse leg [364,365].  
Mononucleated myoblasts when cultured in high serum conditions (10% FBS in DMEM) 
proliferate rapidly and then can be induced to differentiate when switched into low serum 
conditions (2% HS in DMEM). In low serum conditions, the majority of proliferating myoblasts 
withdraw from cell cycle and undergo steps in differentiation. Meantime, a small population 
escape from differentiation, remaining mononucleated and quiescent. Thus, the C2C12 cell culture 
effectively recapitulates the myogenic process ex vivo and serves as a great model to study 
myogenesis. These quiescent cells are termed reserve cells and can be identified by their lack of 
myogenic differentiation markers and enriched expression of cell cycle inhibitors. These 
characteristics of reserve cells are shared by resident satellite cells, rendering them a great analog 
to satellite cells and an useful substitute to study satellite cells [366,367].  
Primary mouse myoblasts, compared with C2C12 cell line, though maybe more demanding to 
work with, are more relevant and reflective of the in vivo environment [368]. Same as C2C12 cell 
line, primary mouse myoblasts when cultured also recapitulate the myogenic process ex vivo. 
Primary mouse myoblasts can be purified and grown extensively in vitro and serve as a rather 
decent model to mimic the in vivo characteristics of muscle cells. The transplantation of these cells 
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can be potentially applied in myoblast-mediated gene therapy [368]. After we obtained preliminary 
data using C2C12 cell line, we validated the results in primary mouse myoblasts.  
To better understand the characteristics of satellite cells, we employed a more relevant model 
system, single fiber culture, which allow for manipulation of satellite cells in a dish [369]. As we 
mentioned in literature review section, the complex behavior of satellite cells during skeletal 
muscle regeneration is tightly regulated by a variety of intrinsic factors, as well as extrinsic factors 
[370,371]. These extrinsic factors constitute satellite cell niche, thus when satellite cells are 
isolated along with single fibers, their niche remain relatively intact, providing a useful tool for 
investigating satellite cells.  
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Materials and Methods 
 
C2C12 cell culture: C2C12 cell line was obtained from American Tissue Culture Collection 
(ATCC). Cells were maintained in growth media (GM) consisting of 10% foetal calf serum (FBS) 
in Dulbecco modified eagle’s medium (DMEM) (HyClone), supplemented with 2mM L-glutamine 
(Invitrogen) and 100μg/ml penicillin/streptomycin (Invitrogen), according to ATCC 
recommendations. Cells were induced to differentiate around 80% confluency by switching into 
differentiation media (DM) consisting of 2% horse serum in DMEM supplemented with 2mM L-
glutamine (Invitrogen) and 100μg/ml penicillin/streptomycin (Invitrogen). Cells were maintained 
in an incubator at 95% humidity, 5% CO2 and 37oC.  
OP9/C2C12 co-culture: C2C12 cells were seeded onto a 10cm plate containing confluent OP9 
stromal cells, which are derived from the calvaria of newborn M-CSF-deficient B6C3F1-
op/op mice [372], and cultured in α-MEM medium (GIBCO/Invitrogen) supplemented with 20% 
FBS and 100μg/ml penicillin/streptomycin (Invitrogen). Co-culture cells were cultured in high 
serum DMEM medium and were induced to differentiate by switching into low serum medium for 
up to 4 days.  
Primary cell culture: Primary myoblasts were isolated from 0 to 3-day-old C57BL/6 mice using 
a modified procedure described by Rando and Blau [368]. Briefly, cells were isolated from 
dissected muscle treated with collagenase/dispase (Sigma-Aldrich), and were pre-plated onto 
uncoated tissue culture plate for 30 min to remove fibroblasts. This 30min pre-plating was repeated 
during the following passages until obtaining a pure population of primary myoblast. Cells were 
maintained in F10 (Gibco) medium supplemented with human basic fibroblast growth factor (b-
FGF, Sigma-Aldrich) and 20% FBS on collage-coated dishes (BD Biosciences). Cells were further 
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expanded and differentiated as described [368]. Myoblasts were never cultured for more than 10 
passages after their date of isolation. 
Fractionation of Myotubes and Reserve cells: C2C12 cells were induced to differentiate for 96 
to 144 h in DM. Media was removed and cells were washed three times with cold 1X PBS 
(phosphate buffered saline) followed by addition of 1 ml of 0.125% trypsin in 1X PBS. MT 
contraction were monitored using an Axiovert 25 (Carl Ziess) light microscope. Trypsin was 
removed upon visual observation of MT contraction followed by addition of 1ml cold 1X PBS. 
Gentle swirling was applied to dislodge MTs, and they were transferred into a 1.5 ml tube. Residual 
MT were washed off by addition of cold 1X PBS. Reserve cells (which remained on the plate) 
were scraped off and transferred into a 1.5 ml tube.  
Antibodies and inhibitors: The following antibodies were obtained from Santa Cruz: Fra-2 Q-20 
(sc-604), c-Jun (H-79) (sc-1694), MyoD (M-318) (sc-760), ERK1 (C16) (sc- 93), Actin (I- 19) (sc-
1616-R), dsRed (C-20) (sc-33354), donkey anti-goat IgG-HRP (sc-2020). The following 
antibodies were purchased from Cell Signalling: MEK 1/2 (#9122), phospho-MEK 1/2 (#9121), 
phospho-p44/p42 MAPK (Thr202/Tyr204) (#9106), phospho-Fra-1 (#3880), phospho-c-Jun 
(#9261). Myogenin (clone F5D) and MyHC (clone MF20) monoclonal antibodies were derived 
from hybridomas purchased from the Developmental Studies Hybridoma Bank (DSHB). Goat 
anti-rabbit IgG-HRP (170-6515) and goat anti-mouse IgG-HRP (170-6516) were purchased from 
BioRad Laboratories. PD98059 (#9900) and UO126 (#9903) was purchased from Cell Signalling.  
Protein extraction and Western blot analysis: Cells were lysed and collected using NP-40 lysis 
buffer (0.5% Nonidet P-40, 50mM Tris-HCl pH 8, 150mM NaCl, 10mM sodium pyrophosphate, 
1mM EDTA pH 8, and 0.1M NaF) containing 10μg/ml leupeptin and aprotinin, 5μg/ml pepstatin 
A, 0.2mM phenylmethylsulfonyl fluoride (PMSF), and 0.5mM sodium orthovanadate. Cytosolic 
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and nuclear extraction was performed using a NE-PER nuclear protein extraction kit 
(Thermoscientific, #78833). Protein concentrations were determined by Bradford protein assay 
(BioRad). Protein extracts were denatured using SDS loading buffer at 95°C for 5 min and then 
subjected to a 10% SDS-PAGE gel, transferred to a polyvinylidene difluoride (PVDF) membrane 
(Millipore), and blocked in 5% skim milk for 1 h prior to primary antibody incubation. Blots were 
incubated with the indicated primary antibody in 5% milk in PBS or Tris buffered saline (TBS)-T 
(10mM Tris-HCl pH 8.0, 150mM NaCl, 0.1% Tween-20) or 5% Bovine serum albumin (BSA) in 
TBS-T at 4 °C overnight with gentle agitation. Appropriate HRP-conjugated secondary antibody 
(1:2000) were added for 2 hours at room temperature. Protein was detected with Enhanced 
Chemiluminescence (ECL) western blotting substrate (Pierce).  
Transfections: For siRNA experiments in C2C12, Lipofectamine (Invitrogen) was used according 
to the manufacturer’s instructions. Cells were then harvested at indicated conditions. Primary 
myoblasts were transiently transfected with siRNA using Lipofectamine RNAiMax (Invitrogen) 
according to the manufacturer’s instructions.  
Gene silencing: Three siRNAs (Mission® siRNA ID’s: SASI_Mm01_00201000, 
SASI_Mm01_00201002, SASI_Mm01_00201004) targeting mouse Fra-2 were purchased from 
Sigma-Aldrich. They were reconstituted in nuclease free water (Ambion) and the concentration 
used was 50nM. Three siRNAs (Mission® siRNA ID’s: SASI_Mm01_00046357, 
SASI_Mm02_00318895, SASI_Mm01_00046359 targeting mouse c-Jun were purchased from 
Sigma-Aldrich. They were reconstituted in nuclease free water (Ambion) and the concentration 
used was 100nM. a universal scrambled RNA was used at the equivalent concentration. 
 Chromatin Immunoprecipitation: Plates were washed briefly with 1X PBS (4°C) to remove 
media. Cells were incubated with 1% formaldehyde for 15 min at RT after which 0.125M of 
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glycine was added. Liquid was aspirated and cells were washed three times with 1X PBS (4°C). 
Cells were scraped in 1 ml of 1X PBS and protease and phosphatase inhibitors (4°C) and 
centrifuged for 5 min at 5000 rpm at 4°C to pellet cells. Cell pellet was resuspended with 1 ml of 
Wash buffer I (10mM HEPES pH 6.5, 0.5mM EGTA, 10mM EDTA, 0.25% Triton X-100, 
protease and phosphatase inhibitors) and incubated on ice for 5 min. Lysate was centrifuged for 5 
min at 3000 rpm at 4°C, pelleted nuclei were resuspended in 1 ml of Wash buffer 2 (10mM, HEPES 
pH 6.5, 0.5mM EGTA, 1mM EDTA, 200mM NaCl, protease and phosphatase inhibitors) and 
incubated for 10 min on ice followed by centrifugation at 5000 rpm for 5 min at 4. To lyse nuclei, 
250μl of SDS lysis buffer (50mM Tris-HCl pH 8.1, 1mM EDTA, 1% SDS, protease and 
phosphatase inhibitors, prepare fresh) was added. DNA was sonicated to approximately 250-500 
bp fragments. Sonicated samples were centrifuged at max speed for 15 min at 4°C to remove 
insoluble materials. Sheared DNA resolved in supernatant, were collected to a clean tube. Sheared 
DNA was incubated with 1μg of Fra-2 primary antibody while protein G dynal magnetic beads 
were blocked using salmon sperm DNA overnight at 4°C. Pre-blocked protein G dynal magnetic 
beads were added to the IP reaction and incubated for 1h at 4°C. The magnetic beads were washed 
with low salt wash buffer (20mM Tris pH 8.1, 2mM EDTA, 150mM NaCl, 1% Triton-X 100, 0.1% 
SDS) followed by washing in high salt buffer (20mM Tris pH 8.1, 2mM EDTA, 500mM NaCl, 1% 
Triton-X 100, 0.1% SDS. Beads were then washed with a third wash buffer (20mM Tris pH 8.1, 
250mM LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA). Protein-DNA complex were eluted 
from beads by incubating with elution buffer (0.1M NaHCO3, 1% SDS) for 30min at room 
temperature. Supernatant was transferred to a clean tube and incubated with 5M NaCl overnight 
at 65°C. Isolated DNA was subjected to purification using the Qiagen PCR clean up kit, as per 
manufactures instructions. 
56 
 
RNA extraction: RNA extraction was carried out using the RNeasy Plus kit (Qiagen) and 
Qiashredder (Qiagen) according to manufacturer’s instructions. cDNA conversion was carried out 
using Superscript III (Invitrogen) according to the manufacturer’s instructions. 
Quantitative PCR: cDNA was diluted 1:10 prior to use. 2.5μl gDNA or cDNA was mixed with 
SYBR Green (BioRad) and 500nM primers in a final volume of 20μl. Each sample was prepared 
in triplicates and analyzed using Rotor-Gene Q (Qiagen). Parameters for qRT-PCR: 30s 95oC, [5s 
95oC, 30s 60oC] x 40 cycles. Fold change (qRT-PCR) was quantified using the ∆∆Ct method. 
Primers used in qRT-PCR are listed in appendix (Figure S6).  
Immunofluorescence: Cells were washed three times with cold 1X PBS and fixed in 4% 
paraformaldehyde in PBS for 10 min and then permeabilized with 0.3% Triton X-100 in PBS for 
5min at room temperature. Cells were blocked in 10% goat serum in 1X PBS for 1 h at room 
temperature and then incubated overnight with indicated primary antibody diluted (1:500) in 1.5% 
goat serum in 1X PBS at 4°C. Cells were washed three times with 1X PBS (10 min each) and then 
incubated with the specified tetramethyl rhodamine isothiocyanate (TRITC) or fluorescein 
isothiocyanate (FITC) conjugated secondary antibody (Sigma-Aldrich) diluted (1:400) in 1.5% 
goat serum for 2 h in dark at room temperature, with 4′,6-diamidino-2-phenylindole (DAPI) for 
nuclear staining (1:10,000; Sigma-Aldrich) in the last 10min. Cells were washed three times with 
1X PBS (10 min each) and then left in 1X PBS at 4°C until imaging. Images were obtained using 
either a Carl Zeiss Axio Observer.Z1 (Photometrics Evolve 512 EMCCD camera) or LSM 700 
AxioObserver microscope. Cells were imaged under 40× (EC Plan-Neofluar; 1.30 numerical 
aperture [NA] in oil), 63× (Plan-Apochromat; 1.40 NA in oil), and 100× (Alpha Plan-Apochromat; 
1.46 NA in oil) objectives, using ZEN image acquisition software. Images were taken as a z-stack 
and projected orthogonally at maximum intensity.  
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Single fibre isolation, culture and immunofluorescence analysis: Myofibers were isolated from 
the extensor digitorum longus (EDL) muscle as described previously [369]. Briefly, the EDLs 
were removed from adult (6–8 weeks old) male mice with both tendons intact and digested with 
collagenase type I (2mg/ml in DMEM; Sigma-Aldrich). The muscles were then transferred to 
horse serum-coated plates, and myofibers were separated by trituration using heat-polished glass 
Pasteur pipettes. Fibers were incubated for up to 72 h in DMEM supplemented with 20% FBS and 
1% chick embryo extract at 37 °C, 5% CO2. For immunocytochemistry, myofibers were fixed in 
2% Paraformaldehyde in 1X PBS for 10 min at room temperature and washed three times with 1X 
PBS. Myofibers were permeabilized in 90% Methanol at -20°C for 6 min and incubated in 
blocking buffer (5% FBS in 1X PBS containing 0.01% triton X-100) for 30 min at room 
temperature prior to antibody incubation. Primary antibodies used were: Monoclonal mouse anti-
Pax7 and anti-Myogenin (clone F5D) both from (DSHB) 1:1, Fra-2 (SantaCruz Q-20) 1:500 and 
phosphor-Fra-1 (Cell Signalling Technology #3880) 1:200. All primary antibodies were incubated 
with fibres overnight at 4°C. Secondary antibody incubation and image procedures are the same 
as for cell culture, mentioned above in Immunofluorescence. 
Statistical analysis: All experiments were performed at least three times. Data are presented as 
means ±SEM. Statistical analysis was done using one-tailed paired student t-test. Differences were 
considered statistically significant, if p<0.05. * is p-value ≤ 0.05, **is p-value ≤ 0.01, *** is p-
value ≤ 0.001. 
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Results 
 
AP-1 expression is maintained in and restricted to myogenic reserve cells during 
differentiation 
 
Under differentiation conditions, C2C12 myoblasts have a binary fate, contributing to one of 
two distinct populations: multi-nucleated myotubes (MTs) or mono-nucleated quiescent “reserve” 
cells (R) that have some properties similar to adult muscle satellite cells (Figure 11A). Those two 
populations can be separated using mild trypsinization to assess their gene expression profile [373]. 
Previous studies in our laboratory have documented that AP-1 expression is maintained throughout 
the differentiation program. Fra-2 is the main Fos related AP-1 subunit expressed under these 
conditions and its stabilization upon phosphorylation by cytokine-mediated ERK1/2 signaling has 
been linked to the regulation of reserve cells and also satellite cells in adult muscle [5,116]. In 
order to better understand the role of AP-1 in muscle progenitor cells during skeletal muscle 
maintenance, we initially characterized the expression profile of AP-1 components during 
myogenesis in the reserve and differentiated populations. C2C12 cells were cultured in high serum 
condition and proliferating myoblasts were harvested when cells reached ~80% confluency. 
Differentiating C2C12 cells were cultured in low serum condition and harvested at the time points 
indicated. Western blotting analysis of this differentiation time course was carried out. MyoD and 
MCK expression were monitored in each immunoblot to assess differentiation. As previously 
reported, through the course of differentiation in the culture as a whole, the expression of several 
AP-1 components was maintained with the exception of Fra-1, whose expression diminished in 
differentiation medium (DM). However, when the reserve and MT populations were separated a 
different pattern of expression emerged in that we observed that the AP-1 factors were highly 
enriched in the undifferentiated reserve cell population and virtually absent in the differentiated 
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myotube population (Figure 11B), suggesting their possible involvement in maintaining the 
reserve cells in an undifferentiated state. Conversely their downregulation in the MT population 
correlates with the differentiated myotube phenotype. The undifferentiated state of the reserve cells 
was further reflected by their mono-nucleated phenotype and lack of differentiation markers such 
as MCK (Figure 11B) and their quiescent state was indicated by their enriched expression of p130 
and p27, both of which are negative cell cycle progression regulators (Figure 11C) [373,374]. We 
also observed several immuno-reactive bands for Fra-2 in western blotting analysis consistent with 
our previous observations concerning ERK signaling to Fra-2 (Figure 11B). In addition, co-
immunoprecipitation assays were performed at different time points to confirm the dimer 
composition of AP-1 in C2C12 cells (Figure 11D).  
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Figure 11. AP-1 expression is restricted to reserve cells. A: A 4-day culture of C2C12 cells were fixed and stained 
with DAPI (blue, nucleus) and MyHC (Red, MT), a marker of differentiation. Mono-nucleated reserved cells (R) and 
multi-nucleated myotubes (MT) are indicated by arrows. Cultures are separated into reserve cells (R) and myotubes 
(MT) using mild trypsinization or unseparated (Total) for subsequent analysis. B: Western blotting analysis was 
performed on the fractionated culture along with proliferating MB in GM and total differentiated culture (T) 
maintained in DM at the time point indicated to assess AP-1 subunit expression. MCK expression was used to indicate 
differentiation, Actin was used as loading control. C: Western blotting analysis was performed on a fractionated 4-
day culture along with proliferating MBs to assess cell progression inhibitor expression. GAPDH was used as loading 
control. D: C2C12 cells were cultured and harvested at the time points indicated. Co-immunoprecipitation assays were 
performed using Fra-2, c- Jun and JunD antibodies as indicated (immunoprecipitation, IP) to show the interactions 
between endogenous AP-1 proteins. IB: immunoblot. 
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Depletion of Fra-2 expression in primary myoblast cultures invokes up-regulation of the cell 
cycle inhibitor p27  
 
    Using a loss of function approach, we next sought to investigate how Fra-2 impacts myogenesis 
and muscle progenitor cells. Previously we reported that loss of Fra-2 expression alters myogenic 
differentiation in C2C12 cells [5]. In an attempt to better understand how Fra-2/AP-1 regulates 
myogenesis, we isolated primary muscle cells from 1-3 days old neonatal mice (Figure 12A, B). 
We observed that Pax7 and Fra-2 are co-expressed in proliferating primary myoblasts. As cells 
progress to differentiation as indicated by Myogenin expression, the expression of Pax7, a satellite 
cell marker, diminished (Figure 12A, B). Depletion of Fra-2 expression was achieved using siRNA 
technology. In conditions where Fra-2 was depleted, we observed an increase in the cell cycle 
inhibitor p27 accompanied by an increase in the early differentiation marker Myogenin and late 
differentiation marker MCK compared to control conditions (Figure 12C). Thus, diminution of 
Fra-2 expression up-regulated both a cell cycle inhibitor (p27) and enhanced progression to 
differentiation, which was reflected by an observable increase in the expression of muscle specific 
differentiation markers (Myogenin and MCK). Interestingly, we observed in earlier experiments 
(Figure 11C), that p27 expression was enriched in reserve cells, where Fra-2 was also enriched. 
Collectively, based on these data, we hypothesized a possible role for Fra-2 in maintaining the 
undifferentiated state in muscle progenitor cells. 
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Figure 12. SiRNA depletion of Fra-2 enhances differentiation and up-regulation of cell cycle inhibitor p27. A: 
(Top panel) Schematic of primary muscle cell isolation and culture. (Bottom left panel) Cells were fixed and stained 
for Pax7 to indicate cells are primary muscle cells, DAPI indicates nucleus. (Bottom left panel) A 24 h culture of 
proliferating primary myoblasts under phase contrast microscopy.  B: Primary muscle cells were harvested at the time 
indicated. Pax7, Fra-2, Myogenin and MyoD expression level were analyzed using western blotting. C: Primary 
myoblasts were transfected with siRNA targeting Fra-2. Cell cultures were harvested at proliferating MB, DM 24 h 
and DM 48 h stages respectively. Western blotting analysis was performed to determine Fra-2 levels and p27 
expression. Myogenin and MCK were also analyzed to indicate differentiation, Actin was used as a loading control. 
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AP-1 expression in satellite cells and primary myoblasts 
 
Reserve cells are a cell culture phenomenon and, in some respects are considered analogous 
to satellite cells due to their commitment to the myogenic lineage, shared mono-nucleated 
morphology and undifferentiated state. Satellite cells are the primary mediators of muscle 
regeneration. In view of the expression profile and loss of function data described above, we 
carried out further experiments to investigate the expression profile and role of Fra-2/AP-1 in 
satellite cells. To further characterize Fra-2’s function in satellite cells, the well characterized 
single fiber culture model from mouse EDL (Extensor digitorum longus) was utilized. Cultures 
were made from 6-8 weeks old male C57BL/6 mice (Figure 13A). Immunofluorescence analysis 
of Fra-2 and Pax7 in single fiber cultures at 48h and 72h was performed (Figure 13B). Fra-2 was 
expressed in Pax7 positive satellites cells (48h) and not in the differentiated myofiber nuclei. In 
our earlier experiments we observed Fra-2 co-expressed with Pax7 in primary myoblasts (Figure 
12A&B). Taken together, we propose that Fra-2 is a marker of myogenic progenitor cells. Pax7 
expression was diminished as cells were differentiating. Expression of Pax7 was maintained in a 
small fraction of the cells at the 72h time point, indicating possible satellite cell pool renewal. Fra-
2 expression was still observed, albeit at lower levels in the majority of satellite cell progeny. To 
verify this, we also performed immunofluorescence analysis of Fra-2 and Myogenin in single fiber 
cultures at 24h and 48h. We observed that Fra-2 was expressed in all of the Myogenin positive 
cells at 24h, while its expression was restricted to a much smaller population at 48h (Figure 13C), 
which indicates that Fra-2 expression is likely extinguished as the cells enter the differentiation 
program. 
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Figure 13. Fra-2 and Pax7 expression in activated satellite cells. A: Schematic of myofiber isolation, culture and 
staining. Myofibers was fixed at 24h after isolation and stained for Pax7 (red) to indicate satellite cells. DAPI (blue) 
indicates nucleus. B: Myofibers were dissected from EDL muscle of adult mice and cultured in a dish for the indicated 
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times (48h and 72h). Fibers were immune-stained for Fra-2 (green) and Pax7 (red) at 48h and 72h in culture. Nuclei 
were stained with DAPI (blue). C: Myofibers were dissected from EDL muscle of adult mice and cultured in a dish 
for the indicated times (24h and 48h). Fibers were immune-stained for Fra-2 (red) and Myogenin (green) at 24h and 
48h in culture. Nuclei were stained with DAPI (blue). 
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ChIP-exo analysis of Fra-2 target genes in skeletal muscle 
 
     To address whether Fra-2 is in fact regulating differential sets of genes in proliferating and 
quiescent muscle progenitor cells, chromatin immunoprecipitation sequencing (ChIP-Seq) 
analysis was performed in proliferating cultured C2C12 myoblasts (GM, ~70% confluency) and 
quiescent reserve cells (DM 4d) using a Fra-2-specific antibody or a rabbit IgG control (Figure 
14A). The efficiency of chromatin sonication was tested before sending to Peconic Genomics for 
sequencing (supplementary Figure 7).  716 gene associated binding events were identified in 
myoblasts, 2060 genes were observed in reserve cells. Nearby genes were identified using 
Genomic Regions Enrichment of Annotations Tool (GREAT) using the 5 + 1 kb basal promoter 
with 1 Mb extension rule [375]. Among the gene list, only 20 of them were common to both 
conditions (Figure 14B). Of interest to us was the identification of  Notch1  in reserve cells and 
the Notch ligand, DLL1, in myoblasts, Notch ligands and receptors have been well established to 
play a key role in satellite cells [162], suggesting that Fra-2 might play a role in regulating satellite 
cells by regulating the expression of Notch signaling components. Previous research showed that 
Notch regulates satellite cell self-renewal through direct transcription of Pax7 [354]. We therefore 
wanted to test whether Fra-2 is playing a role in myogenic progenitors by contributing to the 
regulation of competency for Notch signaling. Genes for HGF and wnt7a, two other known 
proteins which have been shown to play important roles in satellite cell division and activation 
respectively, were also identified [171,220].  
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Figure 14. Identification of Fra-2 target genes in C2C12 myoblasts and reserve cells using ChIP-seq. A: 
Schematic of ChIP-Seq analysis. Proliferation C2C12 (GM) and reserve cells (4d in DM) were collected to identify 
Fra-2 target genes using ChIP-seq. A non-specific IgG antibody was used as a control. B: 716 genes was identified to 
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be associated with Fra-2 in myoblast, 2060 genes in reserve cells, among the genes list, with only 20 of them in 
common and are indicated in Venn diagram.  
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Loss of Fra-2 expression down-regulates Notch ligand and target gene expression 
  
To test whether Notch ligand DLL1 is regulated by Fra-2, we silenced Fra-2 expression using 
siRNA technology. Two independent siRNAs targeting Fra-2 were used. Cells were harvested 24h 
after transfection and followed by RNA isolation using RNeasy Plus Mini Kit. qRT-PCR was 
performed in triplicates. Notch ligand DLL1 and Notch downstream target genes Hes1, Hey1 and 
Hey2 are down-regulated upon Fra-2 depletion (Figure 15A). To test whether this is also true in 
primary muscle cells, we transfected freshly isolated primary myoblast with siRNA targeting Fra-
2 when cells. Efficiency of Fra-2 knockdown in primary myoblasts was assessed using western 
blotting analysis (Figure 15B). We observed the same effect on DLL1 and Notch downstream target 
gene transcripts upon Fra-2 depletion (Figure 15C).  Together, these data indicate that Fra-2 
regulates Notch ligand expression and its downstream genes at the mRNA level.  
Next, we tested whether Notch ligand and its downstream target genes are also regulated by 
c-Jun, a dimerization partner of Fra-2. Freshly isolated primary myoblasts were transfected with 
siRNA targeting c-Jun when cells reached ~50% confluency. Efficiency of c-Jun knockdown in 
primary myoblasts was assessed using western blotting analysis (Figure 15C). We observed no 
effect on Notch ligand and its downstream genes upon c-Jun depletion (Figure 15E). In 
combination with siFra-2 data described above, we propose that DLL1 is indeed a Fra-2 target 
gene and losing Fra-2 but not c-Jun could not be compensated.  
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Figure 15. Notch ligand and its target genes are down-regulated at mRNA level upon Fra-2 knockdown, while 
mRNA levels of these genes are not affected upon c-Jun knockdown. A: C2C12 cells were transfected with a 
scrambled and two independent siRNAs targeted to Fra-2 for 24h. Total RNAs were isolated, followed by cDNA 
conversion and qRT-PCR. β-Actin was used as internal control. Results are means ± SEM of 3 independent 
experiments, performed in triplicates. The asterisk (*) indicates a statistically significant difference (p<0.05), when 
compared with the control cells. B/D: Primary myoblasts were transfected with scrambled siRNA, siRNA to Fra-2 or 
c-Jun and harvested 24h after transfection. Western blotting analysis was performed to indicate Fra-2 and c-Jun 
depletion efficiency at the protein level. C&E: Primary myoblasts were transfected with a scrambled siRNA, siRNA 
to Fra-2 or c-Jun for 24h. Total RNAs were isolated, followed by cDNA conversion and qRT-PCR. β-Actin was used 
as internal control. Results are means ± SEM of 3 independent experiments, performed in triplicates. The asterisk (*) 
indicates a statistically significant difference (p<0.05), when compared with the control cells. 
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Fra-2 regulates Sbno1, a novel Notch downstream effector 
 
Notch signaling has been documented to inhibit myogenesis and plays a critical role in 
maintaining the quiescent state of muscle progenitor cells [358,376]. To better understand how 
Fra-2 regulates Notch signaling during myogenesis and regeneration,  we activated Notch 
signaling using a well-characterized co-culture model, where Notch signaling pathway activation 
is achieved by co-culture of target cells (in our case muscle cells) with the OP9-Delta cells, a stable 
cell line expressing Notch ligands (Deltal) [377]. We observed inhibition of differentiation by 
Notch activation indicated by the absence of early differentiation marker Myogenin and late 
differentiation marker MCK (Figure 16A). To verify this inhibition was indeed caused by Notch 
activation, we treated C2C12 cells with a commercially available γ-secretase inhibitor L-685,458 
(2μM), which inhibits the final cleavage of the Notch receptor, and thus inhibits Notch intracellular 
domain release and subsequent signaling. We observed enhancement of differentiation by the 
inhibitor as indicated by increased expression of MCK (Figure 16B).  
A previous study in our lab identified Sbno1 as a novel downstream effector of Notch signaling 
(unpublished, in preparation). To test whether exogenous expression of Sbno1 has the same 
inhibitory effect on differentiation of muscle cells as activated Notch signaling, primary myoblasts 
were transfected with Sbno1. We observed decreased expression of Myogenin and MCK upon 
exogenous expression of Sbno1 compared to control, indicating inhibition of differentiation 
(Figure 16C).  
In our earlier experiments, we showed Fra-2 regulates Notch ligand and downstream target gene 
expression at the mRNA level (Figure 15A&C). To determine whether Sbno1, the novel Notch 
effector, is also regulated by Fra-2, we transfected freshly isolated primary myoblasts with two 
independent siRNAs targeting Fra-2. We indeed observed diminished expression of Sbno1, 
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suggesting that, like the other Notch target genes, Fra-2 expression is required for Notch mediated 
expression of Sbno1. Interestingly, we also observed increased expression of Numb when Fra2 is 
depleted, which acts as an antagonist for Notch by causing its selective endocytosis and 
degradation. Numb localizes asymmetrically and segregates into one daughter cell, where it 
influences cell fate by repressing signal transduction via the Notch receptor [378]. 
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Figure 16. Fra-2 regulates the expression, a novel Notch downstream effector, Sbno1. A: Co-Culture Model 
System. B: C2C12 cells were co-cultured with the control OP9 cells and OP9-Deltal cells initially in GM and induced 
to differentiate for 96hrs in DM. Total cellular extracts were isolated and equal amount of cell extracts were subject 
to Western blotting analysis for detection of early and late differentiation markers. Actin was used as loading control. 
C: C2C12 cells were treated with γ-secretase inhibitor. Inhibitor was added at the time indicated. Cells were harvested 
after 96hrs in DM. Western blotting analysis was performed to analyze the effect. D: Primary myoblasts were 
transfected with Sbno1 or subject to γ-secretase inhibitor treatment. Cells were harvested at the time indicated and cell 
extracts were subject to Western blotting analysis to monitor differentiation. E: Two independent siRNA targeting 
Fra-2 were transfected in proliferating primary myoblasts. Cells were harvested at the time indicated. Western blot 
analysis was performed to determine level of Fra-2 knockdown and the effect on Sbno1. Actin was used as a loading 
control. 
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Fra-2, acting as downstream effector of ERK1/2 signaling, regulates Pax7 in muscle 
progenitor cells 
 
Notch signaling has been shown to actively promote the self-renewal of muscle progenitor 
cells through direct regulation of Pax7 [354]. Loss of Notch leads to precocious terminal 
differentiation of satellite cells and satellite cell pool exhaustion, reflected by diminished Pax7 
positive cells. In our earlier experiments illustrated in Figure 15C& Figure 16D, we have observed 
that Fra-2 regulates Notch ligand and downstream target genes at the mRNA level, as well as its 
downstream effector Sbno1 at the protein level in primary myoblasts. We were interested to know 
if loss of Fra-2 impacts Pax7 expression in muscle progenitor cells. To address this question, we 
transfected freshly isolated primary muscle cells with two independent siRNAs targeting Fra-2. 
Efficiency of Fra-2 knockdown in primary myoblasts was assessed using western blotting analysis 
(Figure 17A). We observed that loss of Fra-2 results in decreased Pax7 expression at the mRNA 
level (Figure 17B). 
Next we tested whether suppression of Fra-2/AP-1 activity has the same effect as Fra-2 
depletion using a dominant-negative c-Jun (TAM67), which is a previously well characterized 
general trans dominant inhibitor of AP-1 function [379]. Primary cells were transfected with 
TAM67-GFP and cell lysates were subjected to Western blotting and qRT-PCR analysis. We 
observed decreased Pax7 expression upon TAM67-GFP overexpression along with enhanced 
Myogenin expression (Figure 17C&D). This suggests that loss of Pax7 expression upon Fra-2/AP-
1 inhibition leads to precocious differentiation of primary muscle cells.   
    A previous study in our lab documented that Fra-2 is a direct phosphorylation target of 
ERK1/2, and phosphorylated Fra-2 at S320 and T322 stabilizes Fra-2 protein levels [5]. Also 
ERK1/2 has been reported to regulate the reversible quiescence of satellite cells by acting 
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downstream of the receptor for angiopoietin, Tyr kinase TIE2 [380]. As we have observed that 
Fra-2/AP-1 regulates Pax7 expression as illustrated in Figure 17B&D, we tested whether Fra-2 is 
one of the downstream effectors of ERK1/2 pathway in muscle progenitor cells. To test whether 
Fra-2 is regulated by ERK in satellite cells, EDL was isolated from 6-week-old male mice and 
single fibers were obtained by enzyme dissociation. Single fibers were cultured in growth medium 
for 24hr, and then subject to PD098059, UO126 (MEK inhibitors), or DMSO treatment. Cells were 
harvested 24hr after treatment, then analyzed by Western blotting analysis to determine expression 
levels of Fra-2 and Pax7. Upon ERK1/2 inhibition, both Fra-2 and Pax7 expression levels were 
decreased in comparison with controls (Figure 17E). This indicates that ERK signaling maintains 
both Fra-2 and Pax7 expression in muscle progenitor cells.  
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Figure 17. Pax7 is regulated by Fra-2 in muscle progenitor cell. A: Primary myoblasts were transfected with 
scrambled and siRNA to Fra-2. Cells were harvested 24h after transfection. Western blotting analysis was performed 
to indicate Fra-2 depletion efficiency at the protein level. B: Primary myoblasts were transfected with a scrambled 
and siRNA to Fra-2. Total RNA was isolated, followed by cDNA conversion and qRT-PCR. β-Actin was used as 
internal control. Results are means ± SEM of 3 independent experiments, performed in triplicates. The asterisk (*) 
indicates a statistically significant difference (p<0.05), when compared with the control cells. C: Primary myoblasts 
were transfected with pcDNA3 or TAM67-GFP for 24hr. Western blotting analysis was performed to verify exogenous 
expression at the protein level. D: Primary myoblasts were transfected with pcDNA3 or TAM67-GFP for 24hr. RNA 
was isolated and followed by cDNA conversion and qRT-PCR. β-Actin was used as internal control. Results are means 
± SEM of 3 independent experiments, performed in triplicates. The asterisk (*) indicates a statistically significant 
difference (p<0.05), when compared with the control cells. E: Two independent inhibitors targeting MEK, PD98059 
and UO126, were employed in single fiber culture. Western blotting analysis was performed to determine level of 
ERK1/2 inhibition and its effect. 
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Discussion 
 
Extensive literature has documented that AP-1 plays critical roles during embryonic 
development as well as in tumorigenesis [2,3,381], while the role of AP-1 in muscle is still being 
unravelled. Previous studies identified that AP-1 also plays a role in skeletal muscle development 
and implicated its possible involvement in skeletal muscle regeneration [5,116].  In the current 
work, our data suggest that AP-1 might play a role in determining the fate of satellite cells by 
modulating the expression of Pax7 via regulation of Notch signalling in skeletal muscle. These 
data also indicate that the expression of AP-1 is enriched in mono-nucleated “reserve cells” in a 
differentiated culture indicating a possible role in the maintenance of the undifferentiated state. 
We also demonstrate that the expression of Fra-2/AP-1 in activated, proliferating and 
differentiating satellite cells suggests a possible involvement in skeletal muscle regeneration as 
well as in the re-establishment of the satellite cell population. Notch signalling has been 
documented as a crucial regulator of skeletal muscle regeneration [357,358,382][162,358,382,383].  
Using ChIP-exo analysis, Dll1, Hes1 and Hey1 were identified as Fra-2/AP-1 downstream targets. 
Also, these studies document that Fra-2/AP-1 activity, which is regulated by ERK signalling, 
modulates the expression of Sbno1, a novel downstream effector of Notch signalling in myogenic 
cells.  
 
AP-1 plays roles in proliferating primary myoblasts and reserve cells 
  
The expression of AP-1 is maintained in cultured skeletal muscle cells with a relatively similar 
level under proliferating and differentiated conditions [5,116]. The expression of Fra-2 and c-Jun 
are however restricted to mono-nucleated “reserve cells” under differentiated condition [5]. 
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Consistent with these data, here we show that the expression of AP-1 components are maintained 
throughout differentiation and are restricted to the minor undifferentiated population under 
differentiation conditions, indicating their possible role(s) in establishing or maintaining the 
undifferentiated state of “reserve cells” (Figure 11B). One possibility is that AP-1 plays differential 
roles in proliferating myoblasts and undifferentiated reserve cells, considering that they are 
completely different in terms of myogenic status, though both populations have some similarities 
in that they are mono-nucleated and lack differentiation markers. Compared to proliferating 
myoblasts, reserve cells possess enriched negative cell cycle progression regulators such as p130 
and p27, indicating their quiescent state (Figure 11C).  p130 is involved in the determination of 
reserve cells in differentiating myoblasts and can be used as a quiescent marker [384]. Forced 
expression of p130 in mouse C2C12 myoblasts blocks cell cycle progression and inhibits the 
differentiation program accompanied by reduced levels of the muscle-promoting factor MyoD 
[384]. Proliferating myoblasts receive signals from neighbouring cells which are also proliferating, 
while “reserve cells” receive signals from surrounding cells that are differentiated or committed to 
differentiation. Although AP-1 is expressed in both proliferating myoblasts and reserve cells, it is 
no surprise that AP-1 exerts differential sometimes opposite outcomes when affected by differing 
signals. Study has shown that AP-1 mediates hypertrophic growth in adult cardiomyocytes upon 
α-adrenergic stimulation, while the effect of AP-1 may shift from hypertrophy to apoptosis in 
response to additional activation of SMADs [385,386].  
Depletion of Fra-2 in C212 cells enhances the expression of differentiation markers [5]. Our 
data in primary muscle cells agrees with this finding. Here, we show that p27, a cell cycle inhibitor, 
is up-regulated upon Fra-2 knockdown (Figure 12C). Together these data suggest that loss of Fra-
2 and subsequent increased expression of cell cycle inhibitors such as p27 are critical for myoblasts 
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to withdraw from proliferation and commit to differentiation. Here we demonstrate that loss of 
Fra-2 enhances the commitment of myoblasts to the differentiation program and enrichment of 
Fra-2 contributes to the establishment and maintenance of the reserve cell population. Enhanced 
differentiation due to loss of Fra-2 expression is also observed in adipocytes [95], while Fra-2 
deficient osteoblasts display a differentiation defect [53].  
    Our data also indicate that the establishment of reserve cells is more of an actively regulated 
process instead of a passive one. It is achieved partially via repression of proliferation through up-
regulation of cell cycle progression regulators and inhibition of differentiation indicated by the 
absence of differentiation markers (Figure 11B&C).  According to Fra-2/AP-1 ChIP-exo data, 
almost triple times of genes are modulated by Fa-2/AP-1 in reserve cells compared with in 
proliferating myoblasts (Figure 14B). 
 
Fra-2/AP-1 plays a possible role in skeletal muscle regeneration 
 
In our experiments employing the use of the single fiber culture model, we observed that Fra-2 
expression weakens as activated satellite cells proliferate and differentiate, while Pax7 expression 
is maintained in a small fraction of the cells (Figure 13B). The expression of Pax7 in cells in direct 
contact with the fiber or in close proximity lose Pax7 expression, concomitant with reduced 
expression of Fra-2, while cells that are more distal from the fiber maintain their expression of 
Pax7 and Fra-2, thus indicating that signals from the myofiber may be involved in determining the 
fate of proliferating satellite cells. These observations are in agreement with the studies proposing 
asymmetric division of satellite cells [160].   
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Interestingly, we also observed that when all dividing activated satellite cells are in direct 
contact with the myofiber, which indicates symmetric division of satellite cells, Fra-2 expression 
is confined to a minority of proliferating satellite cells as some cells are committed to 
differentiation and start to express the differentiation marker Myogenin. Spatially, Fra-2+MyoG+ 
satellite cells appear to separate from Fra-2
-
MyoG+ cells as well as the myofiber (Figure 13C), 
supporting this idea that cell-cell communication among proliferating satellite cells also plays a 
critical role in cell fate decisions [371].  
This expression pattern of Fra-2 in adult muscle progenitor cells suggests its possible 
involvement during skeletal muscle regeneration, especially in satellite cell fate decisions and 
possibly in the maintenance of the satellite cell pool.  
  
Fra-2/AP-1 regulates cell fate in myogenic cells through Notch signalling  
 
In cultured cells, how clonally equivalent cells assume different fates is still not very clear. 
Lateral inhibition imposed by Notch has been shown to be involved in this process in several 
systems but, so far, not in muscle [326,387,388]. Here we show that activated Notch signalling in 
cultured C2C12 cells inhibits differentiation indicated by decreased MCK expression, and this 
effect can be rescued by Notch inhibition (Figure16A&B). We also identify that the Notch ligand 
Dll1 and receptor Notch1 as Fra-2/AP-1 downstream target genes, which are selectively expressed 
on cells that will later assume different cell fates (Figure 14B). Here we show that depletion of 
Fra-2 down-regulates Hes1 and Pax7 gene expression in cultured primary myoblasts (Figure 17B). 
Inhibition of AP-1 using TAM67 also results in a decrease of Pax7 expression and an increase in 
Myogenin expression consistent with Fra-2 depletion data (Figure 17D). These data suggest that 
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loss of AP-1 leads to cellular differentiation by supressing Notch signalling and subsequently Pax7 
expression. Collectively, these data implicate Fra-2 in the regulation of cell fate by Notch 
signalling in myogenic cells. 
Notch signalling has been extensively investigated in skeletal muscle, revealing both direct and 
indirect effects, as well as contextual roles in regulating satellite cells and also niche establishment 
during skeletal muscle regeneration [350,354,389–391]. Most recently, Notch has been 
documented to activate distinct targets through the same Notch receptor by discriminating between 
ligands [392]. Ectopic expression of Dll1 was shown to promote myogenic differentiation, while 
ectopic expression of Dll4 inhibits it in chick neural crest [392] . Evidence reported here indicates 
that depletion of Fra-2 results in the down-regulation of Dll1 and its downstream genes both in 
cultured C2C12 cells and primary myoblasts (Figure 15A&C), while this effect is not observed 
upon c-Jun depletion (Figure 15E). Our previous studies documented how the variation in AP-1 
complex composition can affect its function [116]. We conclude that Notch regulation by AP-1 
during skeletal muscle regeneration depends primarily on Fra-2 function. Interestingly, c-Jun was 
reported to be critical for the exit of satellite cells from quiescence due to it being a key 
transcriptional target of the PI3K/mTORC1 signaling axis [393].  
Besides regulating the Notch pathway by targeting its ligand/receptor and downstream genes, 
Fra-2/AP-1 can also affect Notch signalling by modulating its downstream effector, Sbno1 
(unpublished data) at the protein level in primary culture (Figure 16D). We also report that loss of 
Fra-2 results in enhanced expression of Numb, a Notch inhibitor, which functions to segregate 
cells asymmetrically, dictate the outcomes of Notch and function as a cell fate determinant 
[394,395]. We conclude that Fra-2/AP-1 functions upstream of Notch signalling and determines 
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whether cells are quiescent, proliferative or assume a differentiated cell fate during muscle 
regeneration.  
 
ERK 1/2 acts upstream of Fra-2/AP-1 in satellite cells 
  
Previous work showed that Fra-2 is a primary ERK substrate in response to cytokine signalling 
in cultured C2C12 cells [5]. ERK1/2 signalling has also been reported to play a complex bi-phasic 
role in myogenesis [396].  Later study revealed that the localization of ERK1/2 dictates its function, 
in which case nuclear p-ERK promotes proliferation by preventing cell cycle exit while its 
cytoplasmic counterpart promotes differentiation [397]. In addition, ERK signalling is involved in 
maintaining the undifferentiated state in skeletal myoblasts by acting down stream of MEK1/2 
activated by CT-1 [398]. Based on these reports, it is reasonable to propose that Fra-2/AP-1 may 
play a complex role in myogenic cells by acting as a direct substrate of ERK signalling. This bi-
phasic role of ERK may explain what we mentioned earlier that Fra-2 plays differential roles in 
proliferating myoblasts and reserve cells.  
To determine whether Fra-2 is regulated by ERK and its possible outcomes in satellite cells, we 
used two MAP kinase inhibitors to block ERK1/2 signalling in the cultured single fiber model. We 
document decreased levels of Fra-2 and Pax7 expression upon ERK inhibition (Figure 17E), 
indicating that Fra-2 is likely acting as a downstream effector of ERK1/2 in satellite cells since 
Fra2 is not expressed in the differentiated myofibers in these conditions, possibly influencing the 
fate of satellite cells via modulation of Pax7 expression. ERK signaling was shown to regulate 
reversible quiescence of the Pax7 satellite cell pool during muscle regeneration by acting 
downstream of Sprouty1 (Spry1), an inhibitor of receptor tyrosine kinase signalling [399,400]. 
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Persistent activation of ERK signalling during adult muscle repair impairs the self-renewal of a 
subset of satellite cells [399]. ERK2 expression is specifically induced and activated by 
phosphorylation upon muscle injury, suggesting a key role in muscle regeneration [235]. This 
induced activation of ERK signaling upon injury is transient in mammals, while sustained ERK 
activation is found in salamander myotube regeneration [401]. Similarly, sustained ERK activation 
was also reported to impair nerve repair in adult Schwann cells [402]. The extent and pattern of 
ERK activation could therefore underlie the differences in regenerative competence between 
species and amongst tissues. In addition, ERK signalling is shown to be essential for zebrafish 
cardiac regeneration and induced expression of a dominant-negative form of MEK1 inhibits this 
process [403].  
We therefore propose that ERK signalling might play a universal role in terms of regulating 
regeneration, and Fra-2/AP-1 as a ubiquitous downstream effector of this pathway maintains its 
expression in myogenic progenitor cells and may regulate the process of regeneration by 
modulation of Notch signalling, a known regulator a skeletal muscle development and regeneration. 
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Summary and future directions 
 
AP-1 is ubiquitously expressed in many tissue types but also has been shown to exert tissue 
specific functions, which may be due to due to its complex and dynamic dimer composition. In 
skeletal muscle, dimer composition shifts from Fra-2:c-Jun to Fra-2:JunD when cells are starting 
to differentiate [116], indicating that each dimer combination may have a unique role in skeletal 
muscle.  
In experiments described here, it is documented that all AP-1 compositions are enriched in 
reserve cells in a fully differentiated myogenic culture, implying that AP-1 may play a role in the 
establishment of the reserve cell pool during skeletal muscle differentiation. In these data, Fra-
2/AP-1 is indicated to play a critical role in myogenic cells by modulating Pax7 expression through 
Notch activity.  Notch function is, itself regulated by AP-1 modulation of its ligand (DLL1), 
receptor (Notch1) and subsequent downstream targets (Hes1/Hey1/Sbno1). Notch ligand and 
receptor are asymmetrically expressed during cell division, which is crucial for cell fate 
specification. Fra-2/AP-1 can further modulate Notch activity through inhibiting Numb, a Notch 
inhibitor, which is also asymmetrically expressed during cell division, allowing for differential 
cell fate. Loss of function using siRNA technology indicates that the effect of AP-1 on Notch 
signaling in myogenic progenitor cells is Fra-2 specific. Further investigation using 
pharmacological MEK/ERK pathway inhibitors UO126 and PD98059 indicate that ERK1/2 
pathway is involved in AP-1 modulation in myogenic cells. We propose that Fra-2/AP-1 plays an 
important role in determining the fate of myogenic cells during proliferation, differentiation and 
satellite cell pool establishment and maintenance. 
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In summary, we provide novel insights into the role of Fra-2/AP-1 in myogenic progenitor cells, 
implicating Fra-2/AP-1 in the maintenance of the skeletal muscle stem cell quiescent phenotype 
and re-establishment of skeletal muscle stem cell pool.  The data contained herein allow the 
following model to be proposed in which Pax7 expression in satellite cells is modulated by AP-
1/Fra-2 through its effect on the competency for Notch signaling (Figure 18). Further experiments 
are needed to confirm this model.  
 
 
Figure 18. Proposed model for the regulation of myogenic progenitor cells by Fra-2. AP-1/Fra-2 regulates muscle 
progenitor cells by influencing competence for Notch signaling. This in turn influences the expression of Notch 
downstream effector genes and ultimately Pax7 expression. 
 
 
These findings have important ramifications to the field of skeletal muscle regeneration and 
potentially in our understanding of the progression of skeletal muscle diseases, such as muscular 
dystrophy, muscle atrophy and muscle weakness. This knowledge may uncover potentially new 
therapeutic targets and alternatives for manipulation of skeletal muscle regeneration postnatally. 
The data described here has been performed on C2C12 myoblasts, primary mouse myoblasts 
and single fiber cultures (ex vivo). Using cultured primary myoblasts and single fiber culture has 
several advantages over using immortalized cell lines (such as C2C12). However, removal of 
satellite cells from the in vivo environment may also alter phenotypic and differentiation properties 
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as a result of isolation from the surrounding cells and structures. Satellite cells have been 
documented to be greatly affected by their niche and surrounding ECM and this was why the single 
fiber analysis was carried out in which the niche and ultrastructure of the muscle fiber is maintained.  
To further the physiological relevance of this work will require progression to an in vivo setting 
to further investigate the role of AP-1 in skeletal muscle regeneration. Blockade of Fra-2/AP-1 by 
delivery of upstream signaling pathway inhibitors in vivo could provide new evidence concerning 
whether Fra-2/AP-1are important in preventing muscle wasting diseases. Using geriatric mice to 
study the expression of AP-1 and its effect on muscle will also provide new insights into the role 
of AP-1 in myogenic progenitor cells and skeletal muscle regeneration. Gene (target genes of AP-
1) and protein (co-factors of AP-1) profiling in young, adult and geriatric mice, or healthy and 
diseased mice will further our understanding the role of AP-1 in myogenic cells at the molecular 
and cellular levels, providing potentially new strategies to treat muscle diseases more effectively. 
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Appendices 
 
Appendix A: Supplementary figures 
 
 
 
Figure S1: Mustn1 and Pax7 are co-expressed in satellite cells.  Myofibers were dissected from EDL muscle of 
adult mice and followed by fixation. Fibers were immune-stained for Mustn1 (green) and Pax7 (red). Nuclei were 
stained with DAPI (blue). Mustn1 gene contains MyoD binding sites and is enriched for AP-1 sites.  
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Figure S2: AP-1 subcellular location in C2C12 cells. C2C12 cells were cultured and harvested at proliferating 
condition. Subcellular fractionation was performed using subcellular protein fractionation kit (Thermo Fisher). EGFR, 
Hsp90 and Sp1 were probed to indicate membrane bound protein, cytoplasmic protein and nuclear protein respectively.  
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Figure S3: Pax7 expression in primary myoblasts diminishes as cells differentiate while MyoD expression 
persists. Primary myoblasts isolated from neonatal mice were cultured and fixed.  Cells were immune-stained for 
MyoD (green) and Pax7 (red). Nuclei were stained with DAPI (blue).  
 
 
Figure S4: Sbno1 and Pax7 co-expresses in proliferating primary myoblasts. Primary myoblasts isolated from 
neonatal mice were cultured and fixed.  Cells were immune-stained for Sbno1 (green) and Pax7 (red). Nuclei were 
stained with DAPI (blue).  
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Figure S5: Primers used in qRT-PCR 
Fra-2 Fwd: 5’-AACTTTGACACCTCGTCCCG-3’ 
Rev: 5’-CCAGGCATATCTACCCGGAAT-3’ 
c-Jun Fwd: 5’AGATGAACTCTTTCTGGCCTGCCT-3’ 
Rev: 5’-ACACTGGGCAGGATACCCAAACAA-3’ 
Pax7 Fwd: 5’-CTGGATGAGGGCTCAGATGT-3’ 
Rev: 5’-GGTTAGCTCCTGCCTGCTTA-3’ 
DLL1 Fwd: 5’-TCAGATAACCCTGACGGAGGC-3’ 
Rev: 5’-AGGTAAGAGTTGCCGAGGTCC-3’ 
Hes1 Fwd: 5’-TGAAGGATTCCAAAAATAAAATTCTCTGGG-3’ 
Rev: 5’-CGCCTCTTCTCCATGATAGGCTTTGATGAC-3’ 
Hey1 Fwd: 5’-CGGACGAGAATGGAAACTTGA-3’ 
Rev: 5’-CGGACGAGAATGGAAACTTGA-3’ 
Hey2 Fwd: 5’-AAGCGCCCTTGTGAGGAAA-3’ 
Rev: 5’-TCGCTCCCCACGTCGAT-3’ 
Myogenin  Fed: 5’-CAGCTCCCTCAACCAGGAG-3’  
Rev: 5’-GACTGCAGGAGGCGCTGT-3’  
β-Actin Fwd: 5’-AAGTGTGACGTTGACATCCGTAA-3’  
Rev: 5’-TGCCTGGGTACATGGTGGTA-3’  
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Figure S6: Testing the efficiency of chromatin sonication. Agarose gel (2%) electrophoresis of sonicated DNA to 
determine the fragment size of the crosslinked chromatin. Ideal DNA sonication is shown with fragment size ranging 
from 200~500 bp. High molecular weight unfragmented DNA can be seen on top of the gel.  
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Appendix B: Selected materials and methods  
 
Cell Culture: 
 
Reagents: 
 DMEM (HyClone) supplemented with 100 μg/ml penicillin/streptomycin (Invitrogen) and 
1% L-glutamine (Invitrogen) (added as required) for C2C12 cells 
 Growth Medium (GM): 10% fetal bovine serum (FBS) 
 Differentiation Medium (DM): 2% horse serum (HS) 
 α-MEM (GIBCO) supplemented with 100 μg/ml penicillin/streptomycin (Invitrogen) and 
1% L-glutamine (Invitrogen) for OP9 cells 
 GM: 20% FBS 
 1X Dulbecco's PBS 
 Versene (VE) (0.2g of EDTA in 1L 1X PBS) 
 0.125% trypsin (HyClone) diluted in VE  
 1% gelatin for coating C2C12 culture plates 
 Freezing Medium: Growth media supplemented with 5% DMSO  
 
Cell Passaging: 
 Aspirate media from cell culture 
 Rinse cells briefly with 5 ml of VE, rinse cells with PBS only if they are primary myoblasts  
 C2C12 and OP9: Remove VE or and add 1 ml of 0.125% trypsin solution to 100mm dish 
or 0.5ml to 60mm dish; primary myoblasts: Remove rinsing solution and add PBS instead   
 Swirl the plate and pipette the trypsin solution or PBS  
 Using a light microscope check if cells are completely detached  
 Add 10 ml of GM and resuspend cells  
 Count the cells in a haemocytometer (optional) and seed a dilution of cells that allows for 
sufficient cell (1:10 dilution is often used for C2C12 cells; 1:3 for OP9 cells; 1:3 for 
primary myoblasts) 
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 Plate cells accordingly: gelatin coated plates for C2C12 and OP9 cell; collagen coated plates 
for primary myoblast. 
 
Inducing Muscle Cell Differentiation:  
 Deplete cells at approximately 80% (60% for primary myoblasts) confluence of growth 
factors and wash cells gently twice with 1X PBS  
 Re-feed cells with 10 ml DM  
 Change media to fresh DM every 48h and monitor differentiation using a light microscope  
 
Freezing Cells: 
 Prepare a cell suspension of approximately 60% (40% for primary myoblasts) confluence 
and pellet the cells by centrifugation at 1500 g 
 Resuspend the cells in freezing medium (1 plate 1 ml medium)  
 Dispense cell suspension into freezing vials (1 plate of cells into 1 vial) 
 Place vials into polystyrene a box in -80 °C freezer and freeze overnight 
 Remove vials from polystyrene box. Place cells in -80 °C freezer for short-term storage, 
and for long term storage, place cells in liquid nitrogen freezer 
 
Thawing Frozen Cells: 
 Remove vial from the liquid-nitrogen freezer  
 Thaw cells quickly in 37 °C water bath 
 Invert vial a few times to dissociate cell clumps  
 Transfer cells to a 15 ml conical tube containing 9 ml of media 
 Centrifuge for 5 min at 1500 g, discard the supernatant and tap tube vigorously to remove 
cell clumps 
 Suspend cells in 10 ml of GM  
 Plate cells in 10 cm culture dish 
  
Preparation of primary myoblasts culture: 
Adaption of protocol by T. A. Rando, and H.M. Blau [368].  
Materials: 
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 Sterile 1X PBS 
 Ham’s F-10 nutrient mixture (GIBCO) supplemented with 100 μg/ml 
penicillin/streptomycin (Invitrogen) (F-10+) 
 DMEM supplemented with 100 μg/ml penicillin/streptomycin (Invitrogen) (DMEM+) 
 Collagenase/Dispase/CaCl2 solution  
 1mg/ml Collagenase/Dispase (diluted in DMEM) 
 2.5 mM CaCl2, add fresh and use immediately 
 F-10-based primary myoblast selection medium  
 F-10++20% FBS+2.5 ng/ml hFGF 
 F-10/DMEM-based primary myoblast growth medium 
 F-10+/DMEM+ (half/half) +20% FBS+2.5 ng/ml hFGF 
 Fusion medium 
 DMEM++5% HS 
Methods: 
 Sacrifice 5-10 neonatal mice by decapitation  
 Rinse mice with 70% ethanol and remove the skin to expose hindlimb muscles 
 Dissect the hindlimb muscles and place them in culture dish on ice in a drop of sterile PBS, 
keep the tissue moist and sterile  
 Mince muscles to a slurry with razor blades in the culture dish in a sterile tissue culture 
hood 
 Add collagenase/dispase/CaCl2 solution to tissue (~2 ml of per gram of tissue) and keep 
mincing for several min  
 Transfer the minced tissue together with collagenase/dispase/CaCl2 solution to a sterile 
tube 
 Incubate at 37°C for 25 min with occasional gentle trituration (make sure it’s a fine slurry) 
 Centrifuge the cells for 5 min at 350 X g  
 Discard the supernatant and resuspend the pellet in 4-10 ml of F-10-based primary 
myoblast selection medium depending on the amount of tissue processed 
 Transfer cells to a 60-100 mm collagen coated culture dish and incubate in a 37°C 5% CO2 
incubator 
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 Change to fresh F-10-based primary myoblast selection medium every 2 days 
 Transfer cells to a new plate if they have been on the same culture dish for more 
than 5 days, regardless of cell density 
 Do not grow cells at less than 10% confluence or over crowded 
 The F-10-based primary myoblast selection medium gives myoblasts a growth 
advantage over fibroblasts 
 Pass cell when they are ready. Split them at no more than 1:5 dilution 
 Discard medium and wash the plate with 1X PBS 
 Leave a small amount of PBS in the dish, incubate at 37°C for 5 min  
 Dislodge cells from the plate by hitting the dish firmly in a sideways fashion against 
the edge of a table top (myoblasts come off more easily compare to fibroblasts)  
 Pre-plate the cells for 15 min on a collagen coated dish  
 Transfer cells in suspension to a new collagen coated dish (leave fibroblasts behind) 
 Repeat pre-plating when passing cells until most of the fibroblasts are gone  
 Switch cells into F-10/DMEM-based primary myoblast growth medium after the 
fibroblasts are no longer visible 
 Myoblasts are more compact and much smaller in diameter compared to fibroblasts 
when cultured on collagen  
 Pure primary myoblasts can be used for experiments immediately, switch into 
differentiation medium around 40% confluence or frozen for storage 
 
Transfection: 
Lipofectamine transfections were performed in 60/100 mm cell culture dishes. The below 
protocols are for transfection of 100 mm plates, and reagents were scaled proportionally to surface 
area for transfection of 60 mm plates. 
Lipofectamine (Invitrogen) transfection in C2C12 cells: 
 Seed cells at 60% confluence in 10 cm plates 24 hours prior to transfection  
 Prepare DNA-lipofectamine mixture 
 Dilute 5 μg of DNA or siRNA (50-100nM) in 500 μl of DMEM (no antibiotics or 
serum)  
 Mix 20 μl of Lipofectamine reagent with 500 μl of serum- and antibiotic-free media 
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 Incubate both mixtures for 5 min at RT 
 Combine DNA-DMEM mixture and lipofectamine-DMEM mixture, mix well and incubate 
for 20-40 min at RT 
 During incubation wash cells twice with 1X PBS and re-feed cells with 3 ml of serum- and 
antibiotic-free media 
 Add DNA-lipofectamine mixture (1ml) drop wise to plates and gently rock 
 Incubate cells with DNA-lipofectamine mixture for 5 h at 37°C and 5% CO2 
 Supplement media with 20% FBS (1ml per plate) and mix well, incubate overnight 
 Wash cells twice with 1X PBS and re-feed cells with 10 ml growth media, let cells recover 
and harvest at desired time points or switch into differentiation media 
 
Lipofectamine 2000 (Invitrogen) transfection in primary myoblasts: 
 Seed the cells at 60% confluence in 10 cm plates 24 hours prior to transfection 
 Prepare DNA-lipofectamine mixture 
 Dilute a total of 10 μg of DNA in 500μl in Opti-MEM medium (Invitrogen) 
 Mix 15 μl of Lipofectamine 2000 reagent with 500 μl Opti-MEM medium 
 Combine the DNA and Lipofectamine mixtures (1ml), mix well and incubate for a 
minimum of 5 min at RT 
 During incubation wash cells twice with 1X PBS and re-feed cells with 4 ml of fresh growth 
medium 
 Add the 1ml of DNA/Lipofectamine mixture drop wise to the plates and gently rock 
 Incubate cells with DNA-lipofectamine mixture overnight at 37°C and 5% CO2 
 Following the incubation, wash cells twice with 1X PBS re-feed cells with 10 ml fresh 
growth medium and allow the cells to recover for a minimum 16 hours prior to harvesting, 
pharmacological treatments or switch into differentiation media 
 
Lipofectamine RNAiMAX (Invitrogen) transfection in primary myoblasts:  
 Seed the cells at 70% confluence in 10 cm plates 24 hours prior to transfection 
 Prepare DNA-lipofectamine mixture 
 Dilute siRNA (50-100nM) in 750 μl in Opti-MEM medium (Invitrogen) 
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 Mix 12.5 μl of RNAiMAX reagent with 750 μl Opti-MEM medium 
 Combine the DNA and Lipofectamine RNAiMAX mixtures (1.5 ml), mix well and 
incubate for a minimum of 5 min at RT 
 During incubation wash cells with 1X PBS and re-feed cells with 3.5 ml of fresh growth 
medium 
 Add the 1ml of DNA/Lipofectamine RNAiMAX mixture drop wise to the plates and gently 
rock 
 Incubate cells with DNA-lipofectamine RNAiMAX mixture overnight at 37°C and 5% 
CO2 
 Following the incubation, wash cells twice with 1X PBS re-feed cells with 10 ml fresh 
growth medium and allow the cells to recover for a minimum 24 hours prior to harvesting 
or switch into differentiation media 
 
Protein Extracts: 
Keep protein samples on ice at all time (unless otherwise directed). Membrane, cytoplasmic and 
nuclear protein extracts were made using the Subcellular Protein Fractionation Kit for Cultured 
Cells (Pierce). 
Reagents: 
 1xPBS (4°C) 
 NP-40 Lysis buffer 
 50 mM Tris, pH 8.0,  
 150 mM NaCl,  
 1 mM Sodium vanadate  
 1 mM PMSF (add fresh) 
 protease inhibitor cocktail (add fresh, Sigma-Aldrich, P-8340) 
 2X SDS sample buffer (Biorad) (supplemented with 7.5% β-mercaptoethanol fresh as 
directed by manufacturer) 
 
Whole Cell Extracts: 
 Remove cells from the 37°C incubator and place on ice.  
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 Pour off media from cells 
 Wash cells twice with cold 1xPBS 
 Add 700 μl cold 1xPBS and gently scrape cells from the plates using a rubber scraper  
 Collect cells (suspended in 1x PBS) into 1.5 ml eppendorph tubes. 
 Spin cells at 1500xg for 5 min at 4°C 
 Aspirate the supernatant and resuspend the pellet with five times (vol/vol) of that volume 
in NP-40 lysis buffer 
 Vortex cells briefly and place on ice, repeat every 10 min for 40 min 
 Centrifuge cell lysate at at 16.1 X 1000 G for 15 min at 4°C, and transfer supernatant to 
new tube 
 Determine protein concentration by Bradford assay and store samples at - 80 °C 
 
Membrane, Cytoplasmic and Nuclear Protein Extracts (Pierce): 
 Wash cells twice with ice-cold 1X PBS 
 Harvest cells with 1 ml trypsin-EDTA and then centrifuge at 500 × g for 5 min 
 Wash cells by suspending the cell pellet with ice-cold 1X PBS 
 Transfer 1-10 × 106 cells to a 1.5mL microcentrifuge tube and pellet cells by centrifugation 
at 500 × g for 2-3 min 
 Use a pipette to carefully remove and discard the supernatant, leaving the cell pellet as dry 
as possible 
 Resuspend cell pellet with ten times (vol/vol) of that volume in ice-cold CEB containing 
protease inhibitors (add fresh) 
For following procedures, maintain the volume ratio of CEB:MEB:NEB:PEB reagents at 
2:2:1:1, respectively. 
 Incubate the tube at 4°C for 10 min with gentle mixing 
 Centrifuge at 500 × g for 5 min. Immediately transfer the supernatant (cytoplasmic extract) 
to a clean pre-chilled tube on ice 
 Resuspend cell pellet in ice-cold MEB containing protease inhibitors (add fresh)  
 Vortex the tube at 16 000 × g for 5 sec and incubate tube at 4°C for 10 min with gentle 
mixing 
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 Centrifuge at 3000 × g for 5 minutes and transfer the supernatant (membrane extract) to a 
clean pre-chilled tube on ice 
 Resuspend cell pellet in ice-cold NEB containing protease inhibitors (add fresh)  
 Vortex on the highest setting for 15 secs and incubate tube at 4°C for 30 min with gentle 
mixing 
 Spin the tube at 5000 × g for 5 min and transfer the supernatant (soluble nuclear extract) 
fraction to a clean pre-chilled tube on ice 
 Prepare chromatin-bound extraction buffer by adding 5µL of 100mM CaCl2 and 3µL of 
Micrococcal Nuclease (300 units) per 100µL of room temperature NEB 
 Resuspend pellet in room temperature NEB containing protease inhibitors, CaCl2 and 
Micrococcal Nuclease 
 Vortex on the highest setting for 15 sec and incubate at RT for 15 min or in a 37°C water 
bath for 5 min 
 Vortex on the highest setting for 15 sec and centrifuge the tube at at 16 000 × g for 5 min  
 Transfer the supernatant (chromatin-bound nuclear extract) fraction to a clean pre-chilled 
tube on ice 
 Determine protein concentration by Bradford assay and analyze samples by Western 
analysis 
 
Bradford Assay: 
Following collection of the cell lysate, the protein concentration can be determined by Bradford 
Assay. 
 Thaw bovine serum album (BSA, 1μg/μl) and protein samples on ice 
 Label 1.5 ml eppendorph tubes with increasing concentrations of BSA (0, 2, 4, 6, 8 μg/μl) 
and appropriate sample names, all conditions are in duplicates  
 Add 800 μl, 798 μl, 786 μl, 794 μl, 792 μl of ddH20 to the tubes with increasing 
concentrations of BSA, and add 799 μl ddH20 to tubes with protein samples  
 Add appropriate volume of BSA for the above labeled tubes accordingly and add 1 μl of 
cell lysate for each sample to the ddH20 
 Add 200 μl of Bradford reagent to each tube (BioRad) 
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 Mix well and incubate for 5 min at RT 
 Determine optical density (OD) at 595nm for each sample using a spectrophotometer 
 Generate a standard curve and use that to calculate protein sample concentrations 
 
SDS-PAGE Analysis: 
Reagents: 
 10% Resolving gel (15ml) 
 5.9 ml ddH20 
 3.8 ml 1.5M Tris pH 8.8 
 5 ml 30% acrylamide; 
 0.15 ml 10% SDS 
 0.15 ml 10% APS 
 0.006 ml TEMED 
 Stacking gel (4ml) 
 2. 7 ml ddH20 
 0.5 ml 1.0 M Tris pH 6.8 
 0.67 ml 30% acrylamide 
 0.04 ml 10% SDS 
 0.04 ml 10% APS 
 0.004 ml TEMED 
 10 X Laemmli (1L) 
 ddH20 800 ml 
 Tris 30.3g 
 Glycine 144.2 g 
 SDS 10g 
 pH to 8.3  
 bring volume up to 1L with ddH20 
 1 X PBS 
Methods: 
 Prepare resolving gel and pour into Hoefer mini-gel apparatus, let the gel sit at RT for a 
minimum of 10 min to polymerize 
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 Pour stacking gel on top of resolving gel and insert appropriate combs, let the gel polmerize 
 Immerse the bottom and centre well of mini-gel apparatus in 1X Laemmli buffer 
 Load equal amounts of protein samples (prepare fresh) on gel 
 Calculate the appropriate volume for 15-20 μg of protein  
 Dilute protein samples with 3X SDS sample buffer 
 Boil samples at 100°C for 6 min, spin briefly, chill on ice for 5 min before loading 
 Run a gel at 80 V through stacking gel and 120 V through resolving gel 
 
Western Immunoblot: 
Reagents: 
 1X Transfer buffer (100ml) (methanol, glycine, Tris Base) 
 Methanol 
 1X PBS and/or 1X TBS 
 Primary and Secondary antibody (as required) 
Blocking buffer, washing solutions, ECL, and antibody diluent were prepared as per 
manufacturer's instruction. 
 
Methods: 
 Transfer protein from SDS-PAGE gel to Immobilon-P (Millipore) membrane by wet 
transfer at 20V for 16-20 h, or at 106V for 1h (use ice pack) 
 Block membrane with 5 % (w/v) skim milk powder in PBS/TBS (depending on primary 
antibody manufacturers’s requirements) for a minimum of 30 min at RT  
 Incubate membrane with primary antibody diluted 1:100-1:10 000 in blocking solution 
overnight at 4 °C with gentle rocking 
 Wash membrane with PBS/TBST (3 X 10 min each) with rocking  
 Incubate membrane with secondary antibody diluted 1:2000-1:100 000 in blocking 
solution for 2 h at RT 
 Wash membrane with PBS/TBST (3 X 10 min each) 
 Prepare chemiluminescence reagents fresh and add to memebrane 
 Incubate for 1-10 min (depending on the antibody) at RT  
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 Expose blot to film and develop using an automated developer in the dark room 
 
Co-immunoprecipitation analysis: 
 Mix 40 μl of ImmunoCruz beads (specie-specific to primary antibody) with 500 μl cold 1X 
PBS 
 Add 1-5μg of primary antibody to PBS-ImmunoCruz beads mixture. Mix well and incubate 
O/N at 4°C with gentle rocking  
 After overnight incubation, wash antibody-beads complex 3x in 1X PBS (cold) by 
centrifugation at max speed for 30 sec at 4°C   
 Prepare protein lysates as described in protein extracts section 
 Dilute 250-1000 μg total protein lysate in 1 ml of NP-40 lysis buffer and add to antibody-
beads complex.  
 Incubate O/N at 4°C with rocking 
 After overnight incubation, wash immuno-complex 3x in 1X PBS (cold) by centrifugation 
at 5000 × g for 30 sec at 4°C  
 Remove supernatant and wash pellet with 1 ml of 1X PBS (cold). 
 Repeat washes twice more 
 Resuspend pellet in 40 μl of 2 X SDS sample buffer and boil at 100°C for 5 min 
 Load supernatant into SDS-PAGE gel (do not transfer beads) and followed by Western 
analysis  
 
Immunofluorescence: 
Reagents:  
 Fixative: paraformaldehyde  
 Permeabilize reagent: 90% ice-cold methanol 
 Blocking reagent: 10% goat serum in 1X PBS 
 
Methods: 
 Wash cells several times with cold 1X PBS 
 Fix cells with 4 % paraformaldehyde in 1X PBS for 10 min at RT 
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 Wash cells three times with cold 1X PBS 
 Permeabilize cells with 90% methanol (cold) for 6 mins at -20°C 
 Block cells with 10% goat serum in PBS at 37 °C for 30 min 
 Incubate cells with primary antibody (1:50 –1:500 dilution) at 4°C for overnight 
 Wash cells three times with 1X PBS 
 Incubate cells with appropriate TRITC/FITC-conjugated secondary antibody (1 :200) in 
dark for 2 h at RT 
 DAPI (4, 6-diamidino-2-phenylindole) staining in dark for 15 min at RT 
 Wash cells several times with RT 1X PBS 
 Add a drop of appropriate mounting media (DAKO) and cover slip  
 Analyze using fluorescence microscopy 
 
RNA Isolation: 
As per Qiagen RNeasy Plus kit. See manufacture’s protocol.  
 
Chromatin Immunoprecipitation: 
Day 1: 
Preparation of cross-linked cells, isolation of nuclei and chromatin preparation: 
 Wash cells with 1X PBS (4°C) 
 Fix cell with 1% formaldehyde (270 μl of 37% formaldehyde diluted in 10 ml of 1X PBS) 
at RT for 10 min 
 Quench cross-linking reaction by adding Glycine stock drop wise to plate at a final 
concentration of 0.125M, incubate for 5 min at RT 
 Place dishes on ice, asperate liquid and dispose into formaldehyde waste 
 Wash plates three times with 1X PBS (4°C), remove PBS and leave the plates as dry as 
possible 
 Scrape cells in 1 ml PBS 4°C containing PMSF and protease inhibitor cocktail, followed 
by centrifugation for 5 min at 5000 rpm at 4°C 
 Remove supernatants and resuspend cells with 1 ml of Wash buffer I  
 10mM HEPES pH 6.5  
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 0.5 mM EGTA  
 10mM EDTA  
 0.25% Triton X-100 
 protease and phosphatase inhibitors 
 Incubate on ice for 5 min followed by centrifugation for 5 min at 3000 rpm at 4°C 
 Remove supernatant and resuspend nuclei in 1 ml of Wash buffer II 
 10mM, HEPES pH 6.5 
 0.5mM EGTA 
 1mM EDTA  
 200mM NaCl 
 protease and phosphatase inhibitors 
 Incubate for 10 min on ice and centrifuge at 5000 rpm for 5 min at 4° 
 Discard supernatant. Continue to day 2 immediately or nuclei samples can be frozen at -
80°C 
  
Day 2: 
A. Nuclear lysis: 
 Add 500 μl of nuclear lysis buffer (prepare fresh) to nuclei 
 50mM Tris-HCl ph 8.1 
 1mM EDTA 
 1% SDS 
 protease and phosphatase inhibitors  
 Shear DNA by sonication into approximately 250-500 bp fragments 
 Centrifuge samples at max speed for 15 min at 4°C to remove insoluble residuals 
 Transfer supernatant to clean new tubes 
o 2 X 200 μl aliquot for IP (Each 200 μl aliquot should have 1 x 106 cells) 
o 2 X 20 μl aliquots for agarose gel and input samples 
 
B. Pre-Block Protein G Dynabeads: 
 Block protein G Dynabeads with salmon sperm DNA in IP dilution buffer, for each IP (152 
μl in total) 
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 15 μl of beads  
 135 μl IP dilution buffer 
o 0.01% SDS 
o 1.1% Triton-X 100 
o 1.2 mM EDTA 
o 16.7 mM Tris-HCL pH 8.1 
o 167 mM NaCl  
 20 μg (2 μl of 10 mg/ml) salmon sperm  
 Incubate overnight at 4°C with gentle rocking  
 Make an extra IP 
 
C. Lysate-antibody incubation: 
 Determine the DNA sample concentration and use 25μg for each IP  
 Dilute DNA sample 1:10 with IP dilution buffer  
 Add 1-2μg of antibody and use equivalent amount of IgG for control 
 Incubate overnight at 4°C with rotation 
 
Day 3: 
Incubation with Dynabeads and recovery of bound DNA: 
 Mix 152 μl of pre-blocked beads to each IP reaction. Incubate at 4°C for 1 h with rotation 
 Remove supernatant using magnet 
 Wash dynabead-bound antibody:chromatin complex with 1 ml of cold IP Wash Buffer I  
 20mM Tris pH 8.1 
 2mM EDTA 
 150mM NaCl 
 1% Triton-X 100 
 0.1% SDS 
 Incubate at 4°C for 5-10 min with rotation and remove supernatant using magnet 
 Wash dynabead-bound antibody:chromatin complexes with 1 ml of cold IP Wash Buffer 
II 
 20mM Tris pH 8.1 
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 2mM EDTA  
 500mM NaCl 
 1% Triton-X 100 
 0.1% SDS 
 Incubate at 4°C for 5-10 min with rotation and remove supernatant using magnet 
 Wash dynabead-bound antibody:chromatin complexes with 1 ml Wash Buffer III  
 20mM Tris pH 8.1 
 25 mM LiCl 
 1% NP-40 
 1% deoxycholate  
 1mM EDTA 
 Incubate at 4°C for 5-10 min with rotation and remove supernatant using magnet 
 Wash dynabead-bound antibody:chromatin complexes twice in TE buffer at 4°C, each time 
10 min and remove supernatant using magnet 
 Free Protein-DNA complexes from Dynabeads by the addition of 300 μl freshly prepared 
Elution Buffer  
 0.1M NaCO3 
 1% SDS 
 
 Incubate with rotation for 30 min at RT 
 Using magnet to attract Dynabeads, transfer the supernatant into clean tubes 
 Treat recovered samples with 12 μl of 5M NaCl 
 Incubate at 65°C overnight 
 
Day 4: 
Proteinase K Treatment: 
 After overnight incubation, treat cell with freshly prepared Proteinase K treatment buffer  
 6 μl 0.5M EDTA 
 12 μl of 1M Tris-HCl pH 6.5 
 1.2 μl of 10mg/ml proteinase K 
 Incubate for 1 h at 45°C  
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DNA Purification (Using Qiagen PCR clean up kit): 
 Purify DNA using Qiagen PCR clean up kit, as per manufactures directions 
 The purified DNA can be analyzed immediately or stored at -20°C 
 
Primary single fibre isolation culture and staining:  
Regents: 
 Fiber dissociation media (prepare fresh), heat to 37°C before use 
 0.02g collagenase I (sigma) diluted in 10 ml DMEM supplemented with 100 μg/ml 
penicillin/streptomycin (DMEM+) 
 2 ml per mice (2 EDL)  
 Fibre isolation media, keep at 37°C  
 DMEM+ supplemented with 20% FBS   
 Fibre growth media, heat to 37°C before use 
 DMEM+ supplemented with 20% FBS and 1% Chick embryo extract (CEE)  
 Fibre Differentiation media, heat to 37°C before use  
 DMEM+ supplemented with 10% HS 
 Fixation solution  
 2% PFA in 1X PBS  
 Blocking buffer  
 1X PBS  
 5% HS or Goat serum  
 1% BSA  
 0.5% Triton X-100  
 0.01% NaAzide 
 
Primary EDL muscle isolation and dissociation: 
 Sacrifice 6-8 weeks old male mice (resting or injured) by cervical dislocation 
 Spray the mice with 70% ethanol and remove the fascia with sterile scissors to expose 
muscles  
 Identify TA muscle, EDL muscle and the tendons attaching to them   
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 Carefully dissect the TA muscle away from tendon (ankle) to tendon (knee) to expose the 
EDL muscle without damaging it 
 Cut the EDL muscle from tendon (ankle) to tendon (knee) and lift it out of the leg, Avoid 
stretching of the EDL muscle during and after isolation  
 Hold the EDL muscle by the tendon part and place it in collagenase I solution 
 Incubate at 37°C for 1 h with occasional shaking (until fibres become loose), and check the 
digesting condition the EDL muscle under an inverted microscope  
 Fill a 10cm plate (pre-coated with HS) with 5 ml of fiber isolation media  
 Transfer the enzyme digested EDL muscle to the plate 
 Wash the EDL muscle three time with fiber isolation media  
 Using autoclaved-flame polished wide bore glass pipette, gently triturate the EDL muscle 
to dissociate fibers from tendons  
 Remove fiber chunks from the plate 
 Place the plate in an incubator and incubate at 37°C for 30 min  
 Wash fibers with fiber isolation media. Only keep the straight and translucent ones and 
discard the hypercontracted ones 
 
Primary single fiber culture:  
 Using autoclaved-flame polished Pasteur pipet, transfer dissociated fibers to a new 6-well 
plate (pre-coated with HS) containing 2 ml fiber growth media 
 Fibers can be fixed immediately and proceed to staining to analyze satellite cells in 
the quiescent stage 
 Culture fibers for 24 h to observe first division 
 Culture fibers 48-72h to observe transition into myocytes (Myogenin activation) 
 Normally, large satellite cell clusters start to appear 72 h post isolation 
 Transfer fibers into fiber differentiation media, and culture for 4-5 days to observe 
differentiation  
 
Single fiber staining: 
 Remove GM or DM and wash fibers three times with 1X PBS  
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 Fix fibers with fixation solution for 5 min at RT 
 Wash fibers three times with 1X PBS 
 Block fibers using blocking buffer O/N at 4°C or 1 h at RT, with shaking  
 Incubate fibers with primary antibody diluted in blocking buffer for 2 h at RT or O/N at 
4°C with shaking (300μl/well) 
 Pax7 1:2  
 Fra-2 1:500  
 p-Fra-2 1:200  
 c-Jun 1:500 
 Myogenin 1:5 
 Wash fibers three times with 1X PBS  
 Incubate fibers with appropriate TRITC/FITC-conjugated secondary antibody (1:1000) in 
dark for 2 h at RT with shaking 
 DAPI (1:10 000) staining in dark for 10 min at RT 
 Wash fibers several times with 1X PBS 
Mounting stained fiber onto slides:  
Materials: 
 Superfrost Plus slides (fisher) microscope slides white  
 Glass covers (22X50)  
 Hydrophobic pen 
Mehtods:  
 Mark border of slides with Hydrophobic pen 
 Transfer fibers on slide and remove excess liquid  
 Add a drop of appropriate mounting media (DAKO), avoid bubbles  
 Spread out fibres properly with tweezers, making sure they are aligned properly and not 
overlapping each other 
 Remove excess mounting media  
 Cover slip, avoid bubbles 
 Dry the slides in the dark and the fluorescence images are captured using a confocal 
immunofluorescence microscopy 
